https://trial.medpath.com/news/final-results-from-cabinet-phase-iii-trial-reinforce-globenewswire 2024-09-16T12:50:51+00:00 weekly 0.7 https://trial.medpath.com/zh/news/final-results-from-cabinet-phase-iii-trial-reinforce-globenewswire 2024-09-16T12:50:51+00:00 weekly 0.7 https://trial.medpath.com/news/september-16-2024-researchers-examine-feasibility-of-enhanced-tsos-intervention-for 2024-09-16T12:50:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/september-16-2024-researchers-examine-feasibility-of-enhanced-tsos-intervention-for 2024-09-16T12:50:17+00:00 weekly 0.7 https://trial.medpath.com/news/final-results-from-cabinet-phase-iii-trial-reinforce-efficacy-benefits-of-cabometyx-r-in 2024-09-16T12:49:05+00:00 weekly 0.7 https://trial.medpath.com/zh/news/final-results-from-cabinet-phase-iii-trial-reinforce-efficacy-benefits-of-cabometyx-r-in 2024-09-16T12:49:05+00:00 weekly 0.7 https://trial.medpath.com/news/clene-granted-in-person-meeting-with-fda-senior-leadership-to-discuss-cnm-au8 2024-09-16T12:42:23+00:00 weekly 0.7 https://trial.medpath.com/zh/news/clene-granted-in-person-meeting-with-fda-senior-leadership-to-discuss-cnm-au8 2024-09-16T12:42:23+00:00 weekly 0.7 https://trial.medpath.com/news/china-grants-btd-to-blenrep-with-bordex-for-multiple-myeloma 2024-09-16T12:41:07+00:00 weekly 0.7 https://trial.medpath.com/zh/news/china-grants-btd-to-blenrep-with-bordex-for-multiple-myeloma 2024-09-16T12:41:07+00:00 weekly 0.7 https://trial.medpath.com/news/velsera-technology-paves-the-way-for-advanced-cancer-diagnostics-with-fda-approval-of 2024-09-16T12:39:11+00:00 weekly 0.7 https://trial.medpath.com/zh/news/velsera-technology-paves-the-way-for-advanced-cancer-diagnostics-with-fda-approval-of 2024-09-16T12:39:11+00:00 weekly 0.7 https://trial.medpath.com/news/mizuho-maintains-neutral-rating-on-apellis-stock-with-steady-price-target-investing-com 2024-09-16T12:37:27+00:00 weekly 0.7 https://trial.medpath.com/zh/news/mizuho-maintains-neutral-rating-on-apellis-stock-with-steady-price-target-investing-com 2024-09-16T12:37:27+00:00 weekly 0.7 https://trial.medpath.com/news/data-from-a-phase-1-trial-of-highfield-biopharmaceuticals-hf1k16-show-the-new-immuno 2024-09-16T12:36:58+00:00 weekly 0.7 https://trial.medpath.com/zh/news/data-from-a-phase-1-trial-of-highfield-biopharmaceuticals-hf1k16-show-the-new-immuno 2024-09-16T12:36:58+00:00 weekly 0.7 https://trial.medpath.com/news/bio-path-holdings-announces-publication-in-biomedicines-biospace 2024-09-16T12:32:18+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bio-path-holdings-announces-publication-in-biomedicines-biospace 2024-09-16T12:32:18+00:00 weekly 0.7 https://trial.medpath.com/news/passage-bio-to-present-positive-interim-data-from-cohort-1-patients-with-ftd-grn-in-uplift 2024-09-16T12:32:18+00:00 weekly 0.7 https://trial.medpath.com/zh/news/passage-bio-to-present-positive-interim-data-from-cohort-1-patients-with-ftd-grn-in-uplift 2024-09-16T12:32:18+00:00 weekly 0.7 https://trial.medpath.com/news/gigapath-ai-model-shows-superior-accuracy-in-predicting-cancer-mutations-and-tumor-burden 2024-09-16T12:30:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/gigapath-ai-model-shows-superior-accuracy-in-predicting-cancer-mutations-and-tumor-burden 2024-09-16T12:30:00+00:00 weekly 0.7 https://trial.medpath.com/news/novartis-aims-for-single-dose-malaria-cure-with-a-novel-moa-long-acting-aryl-sf5-compound 2024-09-16T12:25:49+00:00 weekly 0.7 https://trial.medpath.com/zh/news/novartis-aims-for-single-dose-malaria-cure-with-a-novel-moa-long-acting-aryl-sf5-compound 2024-09-16T12:25:49+00:00 weekly 0.7 https://trial.medpath.com/news/roche-s-injectable-pd-l1-inhibitor-granted-fda-approval-for-multiple-cancer-types-pmlive 2024-09-16T12:21:28+00:00 weekly 0.7 https://trial.medpath.com/zh/news/roche-s-injectable-pd-l1-inhibitor-granted-fda-approval-for-multiple-cancer-types-pmlive 2024-09-16T12:21:28+00:00 weekly 0.7 https://trial.medpath.com/news/new-research-highlights-complexities-of-central-centrifugal-cicatricial-alopecia-in-diverse-populations 2024-09-16T12:21:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-research-highlights-complexities-of-central-centrifugal-cicatricial-alopecia-in-diverse-populations 2024-09-16T12:21:09+00:00 weekly 0.7 https://trial.medpath.com/news/poseida-therapeutics-receives-regenerative-medicine-advanced-therapy-rmat-stock-titan 2024-09-16T12:20:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/poseida-therapeutics-receives-regenerative-medicine-advanced-therapy-rmat-stock-titan 2024-09-16T12:20:17+00:00 weekly 0.7 https://trial.medpath.com/news/infex-therapeutics-first-ncfb-patient-dosed-in-resp-x-phase-iia-study-research-tree 2024-09-16T12:19:45+00:00 weekly 0.7 https://trial.medpath.com/zh/news/infex-therapeutics-first-ncfb-patient-dosed-in-resp-x-phase-iia-study-research-tree 2024-09-16T12:19:45+00:00 weekly 0.7 https://trial.medpath.com/news/pds-biotechnology-corporation-announces-updated-results-from-versatile-002-phase 2024-09-16T12:15:57+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pds-biotechnology-corporation-announces-updated-results-from-versatile-002-phase 2024-09-16T12:15:57+00:00 weekly 0.7 https://trial.medpath.com/news/phase-iii-aranote-trial-shows-nubeqa-r-darolutamide-significantly-reduced-risk-of 2024-09-16T12:10:19+00:00 weekly 0.7 https://trial.medpath.com/zh/news/phase-iii-aranote-trial-shows-nubeqa-r-darolutamide-significantly-reduced-risk-of 2024-09-16T12:10:19+00:00 weekly 0.7 https://trial.medpath.com/news/aethlon-medical-announces-activation-of-royal-adelaide-hospital-to-begin-patient-markets-data 2024-09-16T12:09:33+00:00 weekly 0.7 https://trial.medpath.com/zh/news/aethlon-medical-announces-activation-of-royal-adelaide-hospital-to-begin-patient-markets-data 2024-09-16T12:09:33+00:00 weekly 0.7 https://trial.medpath.com/news/poseida-therapeutics-receives-regenerative-medicine-advanced-therapy-rmat-placera 2024-09-16T12:05:24+00:00 weekly 0.7 https://trial.medpath.com/zh/news/poseida-therapeutics-receives-regenerative-medicine-advanced-therapy-rmat-placera 2024-09-16T12:05:24+00:00 weekly 0.7 https://trial.medpath.com/news/inspiremd-announces-submission-of-premarket-approval-application-to-fda-seeking-u-s 2024-09-16T11:59:40+00:00 weekly 0.7 https://trial.medpath.com/zh/news/inspiremd-announces-submission-of-premarket-approval-application-to-fda-seeking-u-s 2024-09-16T11:59:40+00:00 weekly 0.7 https://trial.medpath.com/news/pivotal-approach-trial-of-transcontm-cnp-navepegritide-achieved-primary-markets-insider 2024-09-16T11:59:40+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pivotal-approach-trial-of-transcontm-cnp-navepegritide-achieved-primary-markets-insider 2024-09-16T11:59:40+00:00 weekly 0.7 https://trial.medpath.com/news/esmo-niagara-backs-imfinzi-in-bladder-cancer-but-will-fda-pharmaphorum 2024-09-16T11:58:24+00:00 weekly 0.7 https://trial.medpath.com/zh/news/esmo-niagara-backs-imfinzi-in-bladder-cancer-but-will-fda-pharmaphorum 2024-09-16T11:58:24+00:00 weekly 0.7 https://trial.medpath.com/news/inspiremd-seeks-fda-approval-for-carotid-stent-system-investing-com 2024-09-16T11:49:51+00:00 weekly 0.7 https://trial.medpath.com/zh/news/inspiremd-seeks-fda-approval-for-carotid-stent-system-investing-com 2024-09-16T11:49:51+00:00 weekly 0.7 https://trial.medpath.com/news/evaxion-reports-promising-phase-2-trial-results-for-cancer-vaccine-investing-com 2024-09-16T11:49:49+00:00 weekly 0.7 https://trial.medpath.com/zh/news/evaxion-reports-promising-phase-2-trial-results-for-cancer-vaccine-investing-com 2024-09-16T11:49:49+00:00 weekly 0.7 https://trial.medpath.com/news/medexus-provides-update-on-treosulfan-nda-review-process-and-extended-pdufa-goal-date 2024-09-16T11:48:34+00:00 weekly 0.7 https://trial.medpath.com/zh/news/medexus-provides-update-on-treosulfan-nda-review-process-and-extended-pdufa-goal-date 2024-09-16T11:48:34+00:00 weekly 0.7 https://trial.medpath.com/news/eli-lilly-announces-fda-approval-for-ebglyss-in-moderate-to-severe-atopic-dermatitis 2024-09-16T11:43:28+00:00 weekly 0.7 https://trial.medpath.com/zh/news/eli-lilly-announces-fda-approval-for-ebglyss-in-moderate-to-severe-atopic-dermatitis 2024-09-16T11:43:28+00:00 weekly 0.7 https://trial.medpath.com/news/blenrep-belantamab-mafodotin-in-combination-receives-breakthrough-therapy-marketscreener 2024-09-16T11:37:45+00:00 weekly 0.7 https://trial.medpath.com/zh/news/blenrep-belantamab-mafodotin-in-combination-receives-breakthrough-therapy-marketscreener 2024-09-16T11:37:45+00:00 weekly 0.7 https://trial.medpath.com/news/biontech-upgraded-by-jp-morgan-with-a-new-price-target-quantisnow 2024-09-16T11:36:47+00:00 weekly 0.7 https://trial.medpath.com/zh/news/biontech-upgraded-by-jp-morgan-with-a-new-price-target-quantisnow 2024-09-16T11:36:47+00:00 weekly 0.7 https://trial.medpath.com/news/zentalis-pharmaceuticals-announces-fda-has-lifted-partial-clinical-hold-on-azenosertib-studies 2024-09-16T11:32:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/zentalis-pharmaceuticals-announces-fda-has-lifted-partial-clinical-hold-on-azenosertib-studies 2024-09-16T11:32:39+00:00 weekly 0.7 https://trial.medpath.com/news/japan-s-mhlw-approves-csl-arcturus-updated-sa-mrna-covid-19-vaccine-for 2024-09-16T11:29:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/japan-s-mhlw-approves-csl-arcturus-updated-sa-mrna-covid-19-vaccine-for 2024-09-16T11:29:39+00:00 weekly 0.7 https://trial.medpath.com/news/phytohealth-corporation-announced-a-new-clinical-study-results-published-at-2024-esmo-congress 2024-09-16T11:23:12+00:00 weekly 0.7 https://trial.medpath.com/zh/news/phytohealth-corporation-announced-a-new-clinical-study-results-published-at-2024-esmo-congress 2024-09-16T11:23:12+00:00 weekly 0.7 https://trial.medpath.com/news/acrivon-therapeutics-promising-trial-results-and-fda-clearance-tipranks-com 2024-09-16T11:20:36+00:00 weekly 0.7 https://trial.medpath.com/zh/news/acrivon-therapeutics-promising-trial-results-and-fda-clearance-tipranks-com 2024-09-16T11:20:36+00:00 weekly 0.7 https://trial.medpath.com/news/pivotal-approach-trial-of-transcontm-cnp-navepegritide-achieved-primary-stock-titan 2024-09-16T11:19:08+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pivotal-approach-trial-of-transcontm-cnp-navepegritide-achieved-primary-stock-titan 2024-09-16T11:19:08+00:00 weekly 0.7 https://trial.medpath.com/news/pds-biotech-announces-updated-results-from-versatile-002-phase-2-clinical-trial 2024-09-16T11:19:03+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pds-biotech-announces-updated-results-from-versatile-002-phase-2-clinical-trial 2024-09-16T11:19:03+00:00 weekly 0.7 https://trial.medpath.com/news/pds-biotechnology-announces-updates-data-from-versatile-002-trial-tipranks-com 2024-09-16T11:15:23+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pds-biotechnology-announces-updates-data-from-versatile-002-trial-tipranks-com 2024-09-16T11:15:23+00:00 weekly 0.7 https://trial.medpath.com/news/passage-bio-to-present-positive-interim-data-from-cohort-1-globenewswire 2024-09-16T11:08:50+00:00 weekly 0.7 https://trial.medpath.com/zh/news/passage-bio-to-present-positive-interim-data-from-cohort-1-globenewswire 2024-09-16T11:08:50+00:00 weekly 0.7 https://trial.medpath.com/news/breakthrough-is-a-game-changer-in-heart-valve-technology-health-tech-world 2024-09-16T11:07:33+00:00 weekly 0.7 https://trial.medpath.com/zh/news/breakthrough-is-a-game-changer-in-heart-valve-technology-health-tech-world 2024-09-16T11:07:33+00:00 weekly 0.7 https://trial.medpath.com/news/novartis-announces-updated-analysis-from-phase-iii-natalee-trial-tipranks-com 2024-09-16T11:05:35+00:00 weekly 0.7 https://trial.medpath.com/zh/news/novartis-announces-updated-analysis-from-phase-iii-natalee-trial-tipranks-com 2024-09-16T11:05:35+00:00 weekly 0.7 https://trial.medpath.com/news/imfinzi-r-durvalumab-plus-imjudo-r-tremelimumab-actl-demonstrated-unprecedented 2024-09-16T11:03:31+00:00 weekly 0.7 https://trial.medpath.com/zh/news/imfinzi-r-durvalumab-plus-imjudo-r-tremelimumab-actl-demonstrated-unprecedented 2024-09-16T11:03:31+00:00 weekly 0.7 https://trial.medpath.com/news/strides-pharma-gets-fda-nod-for-generic-antidepressant-fluoxetine-60-mg-tablet 2024-09-16T11:02:32+00:00 weekly 0.7 https://trial.medpath.com/zh/news/strides-pharma-gets-fda-nod-for-generic-antidepressant-fluoxetine-60-mg-tablet 2024-09-16T11:02:32+00:00 weekly 0.7 https://trial.medpath.com/news/pds-biotech-announces-updated-results-from-versatile-002-globenewswire 2024-09-16T11:02:07+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pds-biotech-announces-updated-results-from-versatile-002-globenewswire 2024-09-16T11:02:07+00:00 weekly 0.7 https://trial.medpath.com/news/boehringer-s-nerandomilast-meets-primary-endpoint-in-pivotal-phase-iii-fibroneertm-ipf-study 2024-09-16T11:01:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/boehringer-s-nerandomilast-meets-primary-endpoint-in-pivotal-phase-iii-fibroneertm-ipf-study 2024-09-16T11:01:30+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-roche-s-ocrevus-zunovo-with-halozyme-enhanze-delivery-tech 2024-09-16T10:55:21+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-roche-s-ocrevus-zunovo-with-halozyme-enhanze-delivery-tech 2024-09-16T10:55:21+00:00 weekly 0.7 https://trial.medpath.com/news/boehringer-s-nerandomilast-meets-primary-endpoint-in-pivotal-phase-iii-fibroneertm-ipf-study 2024-09-16T10:49:54+00:00 weekly 0.7 https://trial.medpath.com/zh/news/boehringer-s-nerandomilast-meets-primary-endpoint-in-pivotal-phase-iii-fibroneertm-ipf-study 2024-09-16T10:49:54+00:00 weekly 0.7 https://trial.medpath.com/news/epitomee-surges-200-in-two-days-on-fda-approval-for-weight-loss-pill-ctech 2024-09-16T10:49:14+00:00 weekly 0.7 https://trial.medpath.com/zh/news/epitomee-surges-200-in-two-days-on-fda-approval-for-weight-loss-pill-ctech 2024-09-16T10:49:14+00:00 weekly 0.7 https://trial.medpath.com/news/antennova-releases-latest-data-of-cd73-inhibitor-atn-037-including-a-dcr-of-89-5-in-a 2024-09-16T10:41:23+00:00 weekly 0.7 https://trial.medpath.com/zh/news/antennova-releases-latest-data-of-cd73-inhibitor-atn-037-including-a-dcr-of-89-5-in-a 2024-09-16T10:41:23+00:00 weekly 0.7 https://trial.medpath.com/news/promising-anti-tumor-activity-and-safety-of-ivonescimab-in-combination-therapies-in-crc 2024-09-16T10:41:23+00:00 weekly 0.7 https://trial.medpath.com/zh/news/promising-anti-tumor-activity-and-safety-of-ivonescimab-in-combination-therapies-in-crc 2024-09-16T10:41:23+00:00 weekly 0.7 https://trial.medpath.com/news/esmo-2024-regeneron-s-melanoma-combo-therapy-benefit-continues-beyond-two-years 2024-09-16T10:31:15+00:00 weekly 0.7 https://trial.medpath.com/zh/news/esmo-2024-regeneron-s-melanoma-combo-therapy-benefit-continues-beyond-two-years 2024-09-16T10:31:15+00:00 weekly 0.7 https://trial.medpath.com/news/pd-1-checkpoint-inhibitor-shows-promise-for-anal-cancer 2024-09-16T10:29:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pd-1-checkpoint-inhibitor-shows-promise-for-anal-cancer 2024-09-16T10:29:17+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approval-boosts-weight-loss-pill-co-epitomee-globes-english-glvbs 2024-09-16T10:28:36+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approval-boosts-weight-loss-pill-co-epitomee-globes-english-glvbs 2024-09-16T10:28:36+00:00 weekly 0.7 https://trial.medpath.com/news/niagara-durvalumab-plus-chemo-improves-efs-and-os-in-cisplatin-eligible-mibc 2024-09-16T10:19:08+00:00 weekly 0.7 https://trial.medpath.com/zh/news/niagara-durvalumab-plus-chemo-improves-efs-and-os-in-cisplatin-eligible-mibc 2024-09-16T10:19:08+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-first-otc-hearing-aid-software-pharmaceutical-executive 2024-09-16T10:18:57+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-first-otc-hearing-aid-software-pharmaceutical-executive 2024-09-16T10:18:57+00:00 weekly 0.7 https://trial.medpath.com/news/in-vivo-car-t-cells-move-into-clinical-trials-nature 2024-09-16T10:18:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/in-vivo-car-t-cells-move-into-clinical-trials-nature 2024-09-16T10:18:13+00:00 weekly 0.7 https://trial.medpath.com/news/patientseek-identifies-a-genetic-signature-that-separates-a4b7-integrin-therapy-responder 2024-09-16T10:09:23+00:00 weekly 0.7 https://trial.medpath.com/zh/news/patientseek-identifies-a-genetic-signature-that-separates-a4b7-integrin-therapy-responder 2024-09-16T10:09:23+00:00 weekly 0.7 https://trial.medpath.com/news/certa-therapeutics-announces-international-non-proprietary-name-for-its-first-in-class 2024-09-16T10:09:23+00:00 weekly 0.7 https://trial.medpath.com/zh/news/certa-therapeutics-announces-international-non-proprietary-name-for-its-first-in-class 2024-09-16T10:09:23+00:00 weekly 0.7 https://trial.medpath.com/news/this-drug-shows-promise-in-extending-bladder-cancer-patients-lives-newsbytes 2024-09-16T09:59:08+00:00 weekly 0.7 https://trial.medpath.com/zh/news/this-drug-shows-promise-in-extending-bladder-cancer-patients-lives-newsbytes 2024-09-16T09:59:08+00:00 weekly 0.7 https://trial.medpath.com/news/dupixent-receives-fda-approval-as-first-crswnp-treatment-pharmaceutical-technology 2024-09-16T09:58:59+00:00 weekly 0.7 https://trial.medpath.com/zh/news/dupixent-receives-fda-approval-as-first-crswnp-treatment-pharmaceutical-technology 2024-09-16T09:58:59+00:00 weekly 0.7 https://trial.medpath.com/news/medsir-presents-new-studies-at-esmo-that-advance-treatment-of-patients-with-poor 2024-09-16T09:50:05+00:00 weekly 0.7 https://trial.medpath.com/zh/news/medsir-presents-new-studies-at-esmo-that-advance-treatment-of-patients-with-poor 2024-09-16T09:50:05+00:00 weekly 0.7 https://trial.medpath.com/news/deep-behavioural-representation-learning-reveals-risk-profiles-for-malignant-ventricular-arrhythmias 2024-09-16T09:38:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/deep-behavioural-representation-learning-reveals-risk-profiles-for-malignant-ventricular-arrhythmias 2024-09-16T09:38:17+00:00 weekly 0.7 https://trial.medpath.com/news/elicio-therapeutics-announces-three-upcoming-presentations-focused-on-its-lymph-node 2024-09-16T09:37:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/elicio-therapeutics-announces-three-upcoming-presentations-focused-on-its-lymph-node 2024-09-16T09:37:09+00:00 weekly 0.7 https://trial.medpath.com/news/pfizer-presents-positive-data-from-phase-2-study-of-ponsegromab-in-patients-with-cancer-cachexia 2024-09-16T09:37:08+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pfizer-presents-positive-data-from-phase-2-study-of-ponsegromab-in-patients-with-cancer-cachexia 2024-09-16T09:37:08+00:00 weekly 0.7 https://trial.medpath.com/news/io-biotech-announces-positive-results-from-phase-2-trial-of-io102-io103-in-the-first-line 2024-09-16T09:37:07+00:00 weekly 0.7 https://trial.medpath.com/zh/news/io-biotech-announces-positive-results-from-phase-2-trial-of-io102-io103-in-the-first-line 2024-09-16T09:37:07+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-ocrevus-zunovotm-as-the-first-and-only-twice-a-year-10-minute-biospace 2024-09-16T09:37:06+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-ocrevus-zunovotm-as-the-first-and-only-twice-a-year-10-minute-biospace 2024-09-16T09:37:06+00:00 weekly 0.7 https://trial.medpath.com/news/daiichi-sankyo-posts-positive-ds-9606-clinical-trial-results-in-solid-tumours 2024-09-16T09:27:54+00:00 weekly 0.7 https://trial.medpath.com/zh/news/daiichi-sankyo-posts-positive-ds-9606-clinical-trial-results-in-solid-tumours 2024-09-16T09:27:54+00:00 weekly 0.7 https://trial.medpath.com/news/natera-announces-three-new-signatera-publications-includes-groundbreaking-overall 2024-09-16T09:26:06+00:00 weekly 0.7 https://trial.medpath.com/zh/news/natera-announces-three-new-signatera-publications-includes-groundbreaking-overall 2024-09-16T09:26:06+00:00 weekly 0.7 https://trial.medpath.com/news/lilly-secures-fda-approval-for-ebglyss-to-treat-atopic-dermatitis 2024-09-16T09:22:21+00:00 weekly 0.7 https://trial.medpath.com/zh/news/lilly-secures-fda-approval-for-ebglyss-to-treat-atopic-dermatitis 2024-09-16T09:22:21+00:00 weekly 0.7 https://trial.medpath.com/news/daiichi-sankyo-posts-positive-ds-9606-clinical-trial-results-in-solid-tumours-yahoo-finance 2024-09-16T09:18:57+00:00 weekly 0.7 https://trial.medpath.com/zh/news/daiichi-sankyo-posts-positive-ds-9606-clinical-trial-results-in-solid-tumours-yahoo-finance 2024-09-16T09:18:57+00:00 weekly 0.7 https://trial.medpath.com/news/immunotherapy-drugs-extend-survival-for-patients-with-advanced-melanomas 2024-09-16T09:09:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/immunotherapy-drugs-extend-survival-for-patients-with-advanced-melanomas 2024-09-16T09:09:09+00:00 weekly 0.7 https://trial.medpath.com/news/novartis-kisqali-r-shows-deepening-benefit-in-new-analysis-reducing-the-risk-of-recurrence 2024-09-16T08:49:52+00:00 weekly 0.7 https://trial.medpath.com/zh/news/novartis-kisqali-r-shows-deepening-benefit-in-new-analysis-reducing-the-risk-of-recurrence 2024-09-16T08:49:52+00:00 weekly 0.7 https://trial.medpath.com/news/esmo-2024-late-breaking-data-phase-iii-aranote-trial-shows-nubeqa-r-darolutamide 2024-09-16T08:49:10+00:00 weekly 0.7 https://trial.medpath.com/zh/news/esmo-2024-late-breaking-data-phase-iii-aranote-trial-shows-nubeqa-r-darolutamide 2024-09-16T08:49:10+00:00 weekly 0.7 https://trial.medpath.com/news/esmo-2024-late-breaking-data-phase-iii-aranote-trial-shows-nubeqa-r-darolutamide 2024-09-16T08:44:58+00:00 weekly 0.7 https://trial.medpath.com/zh/news/esmo-2024-late-breaking-data-phase-iii-aranote-trial-shows-nubeqa-r-darolutamide 2024-09-16T08:44:58+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-tremfya-r-for-ulcerative-colitis-treatment-promising-new-hope-for-patients 2024-09-16T08:32:40+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-tremfya-r-for-ulcerative-colitis-treatment-promising-new-hope-for-patients 2024-09-16T08:32:40+00:00 weekly 0.7 https://trial.medpath.com/news/novartis-kisqali-r-shows-deepening-benefit-in-new-analysis-globenewswire 2024-09-16T08:19:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/novartis-kisqali-r-shows-deepening-benefit-in-new-analysis-globenewswire 2024-09-16T08:19:17+00:00 weekly 0.7 https://trial.medpath.com/news/gv20-therapeutics-reports-first-clinical-data-for-ai-designed-checkpoint-inhibitor-gv20-0251-in-advanced-solid-tumors 2024-09-16T08:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/gv20-therapeutics-reports-first-clinical-data-for-ai-designed-checkpoint-inhibitor-gv20-0251-in-advanced-solid-tumors 2024-09-16T08:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/diffuse-large-b-cell-lymphoma-is-curable-how-new-drug-polatuzumab-is-working-wonders 2024-09-16T07:50:55+00:00 weekly 0.7 https://trial.medpath.com/zh/news/diffuse-large-b-cell-lymphoma-is-curable-how-new-drug-polatuzumab-is-working-wonders 2024-09-16T07:50:55+00:00 weekly 0.7 https://trial.medpath.com/news/feasibility-and-safety-of-pd-1-blockades-among-elderly-patients-with-p-dove-medical-press 2024-09-16T07:41:28+00:00 weekly 0.7 https://trial.medpath.com/zh/news/feasibility-and-safety-of-pd-1-blockades-among-elderly-patients-with-p-dove-medical-press 2024-09-16T07:41:28+00:00 weekly 0.7 https://trial.medpath.com/news/fda-finalizes-guidance-on-dose-optimization-for-oncology-therapies-clinical-leader 2024-09-16T07:41:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-finalizes-guidance-on-dose-optimization-for-oncology-therapies-clinical-leader 2024-09-16T07:41:13+00:00 weekly 0.7 https://trial.medpath.com/news/roche-ocrevus-zunovo-approved-by-the-fda-marketscreener 2024-09-16T07:37:06+00:00 weekly 0.7 https://trial.medpath.com/zh/news/roche-ocrevus-zunovo-approved-by-the-fda-marketscreener 2024-09-16T07:37:06+00:00 weekly 0.7 https://trial.medpath.com/news/lilly-s-ebglyss-gains-approval-for-patients-12-years-and-older 2024-09-16T07:31:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/lilly-s-ebglyss-gains-approval-for-patients-12-years-and-older 2024-09-16T07:31:01+00:00 weekly 0.7 https://trial.medpath.com/news/esmo-2024-trop2-directed-adcs-show-promise-in-recurrent-gynecological-cancers 2024-09-16T07:21:40+00:00 weekly 0.7 https://trial.medpath.com/zh/news/esmo-2024-trop2-directed-adcs-show-promise-in-recurrent-gynecological-cancers 2024-09-16T07:21:40+00:00 weekly 0.7 https://trial.medpath.com/news/alphamab-oncology-presented-the-latest-clinical-data-from-two-studies-on-anti-her2 2024-09-16T07:10:48+00:00 weekly 0.7 https://trial.medpath.com/zh/news/alphamab-oncology-presented-the-latest-clinical-data-from-two-studies-on-anti-her2 2024-09-16T07:10:48+00:00 weekly 0.7 https://trial.medpath.com/news/esmo-2024-tigit-race-tightens-with-first-look-at-gsk-iteos-s-tigit-in-nsclc 2024-09-16T07:07:24+00:00 weekly 0.7 https://trial.medpath.com/zh/news/esmo-2024-tigit-race-tightens-with-first-look-at-gsk-iteos-s-tigit-in-nsclc 2024-09-16T07:07:24+00:00 weekly 0.7 https://trial.medpath.com/news/new-survey-reveals-12-of-americans-suffer-from-chronic-insomnia-as-sleep-health-concerns-rise 2024-09-16T07:06:07+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-survey-reveals-12-of-americans-suffer-from-chronic-insomnia-as-sleep-health-concerns-rise 2024-09-16T07:06:07+00:00 weekly 0.7 https://trial.medpath.com/news/india-formalises-industry-partnerships-for-phase-one-clinical-trials-healthcare-asia 2024-09-16T06:59:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/india-formalises-industry-partnerships-for-phase-one-clinical-trials-healthcare-asia 2024-09-16T06:59:04+00:00 weekly 0.7 https://trial.medpath.com/news/bavarian-nordic-s-mpox-vaccine-approved-by-who-medwatch 2024-09-16T06:56:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bavarian-nordic-s-mpox-vaccine-approved-by-who-medwatch 2024-09-16T06:56:04+00:00 weekly 0.7 https://trial.medpath.com/news/exact-sciences-colon-cancer-blood-test-shows-initial-promise-stat-news 2024-09-16T06:46:46+00:00 weekly 0.7 https://trial.medpath.com/zh/news/exact-sciences-colon-cancer-blood-test-shows-initial-promise-stat-news 2024-09-16T06:46:46+00:00 weekly 0.7 https://trial.medpath.com/news/neoadjuvant-pembrolizumab-plus-chemotherapy-followed-by-adjuvant-pharmacy-times 2024-09-16T06:43:32+00:00 weekly 0.7 https://trial.medpath.com/zh/news/neoadjuvant-pembrolizumab-plus-chemotherapy-followed-by-adjuvant-pharmacy-times 2024-09-16T06:43:32+00:00 weekly 0.7 https://trial.medpath.com/news/torl-biotherapeutics-presents-updated-phase-1-results-of-novel-claudin-6-targeted-biospace 2024-09-16T06:41:24+00:00 weekly 0.7 https://trial.medpath.com/zh/news/torl-biotherapeutics-presents-updated-phase-1-results-of-novel-claudin-6-targeted-biospace 2024-09-16T06:41:24+00:00 weekly 0.7 https://trial.medpath.com/news/esmo-incyte-s-pd-1-treads-new-ground-in-anal-cancer-pharmaphorum 2024-09-16T06:37:23+00:00 weekly 0.7 https://trial.medpath.com/zh/news/esmo-incyte-s-pd-1-treads-new-ground-in-anal-cancer-pharmaphorum 2024-09-16T06:37:23+00:00 weekly 0.7 https://trial.medpath.com/news/erteilung-des-status-eines-therapiedurchbruchs-fur-sanbexin-sublingualtabletten-durch-die 2024-09-16T06:34:53+00:00 weekly 0.7 https://trial.medpath.com/zh/news/erteilung-des-status-eines-therapiedurchbruchs-fur-sanbexin-sublingualtabletten-durch-die 2024-09-16T06:34:53+00:00 weekly 0.7 https://trial.medpath.com/news/imfinzi-plus-imjudo-demonstrated-unprecedented-overall-survival-in-advanced-liver-cancer 2024-09-16T06:34:05+00:00 weekly 0.7 https://trial.medpath.com/zh/news/imfinzi-plus-imjudo-demonstrated-unprecedented-overall-survival-in-advanced-liver-cancer 2024-09-16T06:34:05+00:00 weekly 0.7 https://trial.medpath.com/news/imfinzi-plus-imjudo-demonstrated-unprecedented-overall-survival-in-advanced-liver-cancer 2024-09-16T06:32:57+00:00 weekly 0.7 https://trial.medpath.com/zh/news/imfinzi-plus-imjudo-demonstrated-unprecedented-overall-survival-in-advanced-liver-cancer 2024-09-16T06:32:57+00:00 weekly 0.7 https://trial.medpath.com/news/l-agence-americaine-des-produits-alimentaires-et-medicamenteux-fda-accorde-pr-newswire 2024-09-16T06:26:51+00:00 weekly 0.7 https://trial.medpath.com/zh/news/l-agence-americaine-des-produits-alimentaires-et-medicamenteux-fda-accorde-pr-newswire 2024-09-16T06:26:51+00:00 weekly 0.7 https://trial.medpath.com/news/roche-s-ocrevus-zunovo-gets-fda-approval-to-treat-relapsing-and-progressive 2024-09-16T06:20:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/roche-s-ocrevus-zunovo-gets-fda-approval-to-treat-relapsing-and-progressive 2024-09-16T06:20:39+00:00 weekly 0.7 https://trial.medpath.com/news/investigational-rinatabart-sesutecan-rina-s-shows-promising-anti-tumor-activity-as-biospace 2024-09-16T06:15:19+00:00 weekly 0.7 https://trial.medpath.com/zh/news/investigational-rinatabart-sesutecan-rina-s-shows-promising-anti-tumor-activity-as-biospace 2024-09-16T06:15:19+00:00 weekly 0.7 https://trial.medpath.com/news/fda-s-biosimilar-landscape-growing-market-share-and-policy-changes-shape-future-access 2024-09-16T06:10:51+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-s-biosimilar-landscape-growing-market-share-and-policy-changes-shape-future-access 2024-09-16T06:10:51+00:00 weekly 0.7 https://trial.medpath.com/news/keynote-006-study-of-pembrolizumab-shows-continued-survival-benefits-in-advanced-melanoma 2024-09-16T06:07:55+00:00 weekly 0.7 https://trial.medpath.com/zh/news/keynote-006-study-of-pembrolizumab-shows-continued-survival-benefits-in-advanced-melanoma 2024-09-16T06:07:55+00:00 weekly 0.7 https://trial.medpath.com/news/bicycle-therapeutics-presents-updated-clinical-results-across-oncology-pipeline-at-esmo 2024-09-16T05:57:15+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bicycle-therapeutics-presents-updated-clinical-results-across-oncology-pipeline-at-esmo 2024-09-16T05:57:15+00:00 weekly 0.7 https://trial.medpath.com/news/alphamab-oncology-presented-the-latest-clinical-data-from-two-studies-on-anti-her2 2024-09-16T05:32:19+00:00 weekly 0.7 https://trial.medpath.com/zh/news/alphamab-oncology-presented-the-latest-clinical-data-from-two-studies-on-anti-her2 2024-09-16T05:32:19+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-ocrevus-zunovotm-as-the-first-and-only-twice-a-year-10-minute 2024-09-16T05:17:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-ocrevus-zunovotm-as-the-first-and-only-twice-a-year-10-minute 2024-09-16T05:17:01+00:00 weekly 0.7 https://trial.medpath.com/news/sutro-biopharma-announces-updated-data-from-phase-1b-study-of-luvelta-in-combination 2024-09-16T05:16:54+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sutro-biopharma-announces-updated-data-from-phase-1b-study-of-luvelta-in-combination 2024-09-16T05:16:54+00:00 weekly 0.7 https://trial.medpath.com/news/rybrevant-r-amivantamab-plus-chemotherapy-shows-positive-overall-survival-trend 2024-09-16T05:16:54+00:00 weekly 0.7 https://trial.medpath.com/zh/news/rybrevant-r-amivantamab-plus-chemotherapy-shows-positive-overall-survival-trend 2024-09-16T05:16:54+00:00 weekly 0.7 https://trial.medpath.com/news/us-fda-approves-eli-lilly-s-drug-for-eczema-express-pharma 2024-09-16T05:08:44+00:00 weekly 0.7 https://trial.medpath.com/zh/news/us-fda-approves-eli-lilly-s-drug-for-eczema-express-pharma 2024-09-16T05:08:44+00:00 weekly 0.7 https://trial.medpath.com/news/rp1-nivolumab-combo-shows-durable-responses-favorable-safety-in-melanoma 2024-09-16T05:07:28+00:00 weekly 0.7 https://trial.medpath.com/zh/news/rp1-nivolumab-combo-shows-durable-responses-favorable-safety-in-melanoma 2024-09-16T05:07:28+00:00 weekly 0.7 https://trial.medpath.com/news/association-between-intensive-blood-pressure-lowering-and-stroke-free-survival-among 2024-09-16T05:07:24+00:00 weekly 0.7 https://trial.medpath.com/zh/news/association-between-intensive-blood-pressure-lowering-and-stroke-free-survival-among 2024-09-16T05:07:24+00:00 weekly 0.7 https://trial.medpath.com/news/novavax-2024-2025-formula-covid-19-vaccine-available-at-major-pharmacies-across-the-u-s 2024-09-16T04:58:52+00:00 weekly 0.7 https://trial.medpath.com/zh/news/novavax-2024-2025-formula-covid-19-vaccine-available-at-major-pharmacies-across-the-u-s 2024-09-16T04:58:52+00:00 weekly 0.7 https://trial.medpath.com/news/early-data-shows-mrna-4359-may-benefit-patients-with-advanced-solid-cancers 2024-09-16T04:38:47+00:00 weekly 0.7 https://trial.medpath.com/zh/news/early-data-shows-mrna-4359-may-benefit-patients-with-advanced-solid-cancers 2024-09-16T04:38:47+00:00 weekly 0.7 https://trial.medpath.com/news/kura-oncology-inc-latest-stock-news-market-updates 2024-09-16T04:29:57+00:00 weekly 0.7 https://trial.medpath.com/zh/news/kura-oncology-inc-latest-stock-news-market-updates 2024-09-16T04:29:57+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-roche-s-tecentriq-hybreza-the-first-and-only-subcutaneous-anti-pd-l-cancer 2024-09-16T04:17:24+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-roche-s-tecentriq-hybreza-the-first-and-only-subcutaneous-anti-pd-l-cancer 2024-09-16T04:17:24+00:00 weekly 0.7 https://trial.medpath.com/news/5-late-stage-mrna-vaccines-to-watch-biospace 2024-09-16T04:15:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/5-late-stage-mrna-vaccines-to-watch-biospace 2024-09-16T04:15:26+00:00 weekly 0.7 https://trial.medpath.com/news/fda-action-alert-bms-merck-sanofi-regeneron-and-more-biospace 2024-09-16T04:15:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-action-alert-bms-merck-sanofi-regeneron-and-more-biospace 2024-09-16T04:15:26+00:00 weekly 0.7 https://trial.medpath.com/news/fda-action-alert-bms-merck-sanofi-regeneron-and-more-biospace 2024-09-16T04:15:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-action-alert-bms-merck-sanofi-regeneron-and-more-biospace 2024-09-16T04:15:26+00:00 weekly 0.7 https://trial.medpath.com/news/dimerix-enters-key-collaboration-to-further-boost-action3-trial-recruitment-in-uk 2024-09-16T03:05:41+00:00 weekly 0.7 https://trial.medpath.com/zh/news/dimerix-enters-key-collaboration-to-further-boost-action3-trial-recruitment-in-uk 2024-09-16T03:05:41+00:00 weekly 0.7 https://trial.medpath.com/news/remarkable-clinical-trial-results-shared-internationally-ansto 2024-09-16T02:16:46+00:00 weekly 0.7 https://trial.medpath.com/zh/news/remarkable-clinical-trial-results-shared-internationally-ansto 2024-09-16T02:16:46+00:00 weekly 0.7 https://trial.medpath.com/news/clinical-trial-breakthrough-shared-globally-mirage-news 2024-09-16T02:13:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/clinical-trial-breakthrough-shared-globally-mirage-news 2024-09-16T02:13:09+00:00 weekly 0.7 https://trial.medpath.com/news/booker-schmitt-paul-king-braun-whitehouse-kennedy-lujan-blumenthal-introduce-the 2024-09-16T01:21:29+00:00 weekly 0.7 https://trial.medpath.com/zh/news/booker-schmitt-paul-king-braun-whitehouse-kennedy-lujan-blumenthal-introduce-the 2024-09-16T01:21:29+00:00 weekly 0.7 https://trial.medpath.com/news/t-dxd-maintains-qol-delays-pain-deterioration-in-hr-her2-low-ultralow-mbc 2024-09-16T01:12:50+00:00 weekly 0.7 https://trial.medpath.com/zh/news/t-dxd-maintains-qol-delays-pain-deterioration-in-hr-her2-low-ultralow-mbc 2024-09-16T01:12:50+00:00 weekly 0.7 https://trial.medpath.com/news/digital-support-app-launches-in-uk-to-address-rising-youth-cancer-cases 2024-09-16T01:07:18+00:00 weekly 0.7 https://trial.medpath.com/zh/news/digital-support-app-launches-in-uk-to-address-rising-youth-cancer-cases 2024-09-16T01:07:18+00:00 weekly 0.7 https://trial.medpath.com/news/esmo-2024-anlotinib-and-penpulimab-gather-attention-in-hcc-with-apollo-results 2024-09-16T00:43:58+00:00 weekly 0.7 https://trial.medpath.com/zh/news/esmo-2024-anlotinib-and-penpulimab-gather-attention-in-hcc-with-apollo-results 2024-09-16T00:43:58+00:00 weekly 0.7 https://trial.medpath.com/news/esmo-2024-updates-in-penile-cancer-urotoday 2024-09-16T00:40:57+00:00 weekly 0.7 https://trial.medpath.com/zh/news/esmo-2024-updates-in-penile-cancer-urotoday 2024-09-16T00:40:57+00:00 weekly 0.7 https://trial.medpath.com/news/who-approves-mpox-vaccine-for-babies-without-clinical-trials-the-conservative-woman 2024-09-16T00:38:37+00:00 weekly 0.7 https://trial.medpath.com/zh/news/who-approves-mpox-vaccine-for-babies-without-clinical-trials-the-conservative-woman 2024-09-16T00:38:37+00:00 weekly 0.7 https://trial.medpath.com/news/esmo-2024-dll-3-targeted-therapy-for-neuroendocrine-prostate-cancer-urotoday 2024-09-16T00:00:45+00:00 weekly 0.7 https://trial.medpath.com/zh/news/esmo-2024-dll-3-targeted-therapy-for-neuroendocrine-prostate-cancer-urotoday 2024-09-16T00:00:45+00:00 weekly 0.7 https://trial.medpath.com/news/ctdna-based-molecular-residual-disease-and-survival-in 2024-09-16T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ctdna-based-molecular-residual-disease-and-survival-in 2024-09-16T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-challenges-abbvie-s-serena-williams-ubrelvy-ad-for-misleading-migraine-claims 2024-09-15T23:49:42+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-challenges-abbvie-s-serena-williams-ubrelvy-ad-for-misleading-migraine-claims 2024-09-15T23:49:42+00:00 weekly 0.7 https://trial.medpath.com/news/10-year-data-from-checkmate-067-confirms-survival-advantage-of-nivolumab-in-advanced 2024-09-15T23:44:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/10-year-data-from-checkmate-067-confirms-survival-advantage-of-nivolumab-in-advanced 2024-09-15T23:44:26+00:00 weekly 0.7 https://trial.medpath.com/news/sintilimab-combined-with-anlotinib-and-chemotherapy-as-second-line-or-later-therapy-in-nature 2024-09-15T23:30:31+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sintilimab-combined-with-anlotinib-and-chemotherapy-as-second-line-or-later-therapy-in-nature 2024-09-15T23:30:31+00:00 weekly 0.7 https://trial.medpath.com/news/radium-223-enhances-outcomes-with-enzalutamide-in-metastatic-castration-resistant 2024-09-15T23:00:21+00:00 weekly 0.7 https://trial.medpath.com/zh/news/radium-223-enhances-outcomes-with-enzalutamide-in-metastatic-castration-resistant 2024-09-15T23:00:21+00:00 weekly 0.7 https://trial.medpath.com/news/fecal-microbiota-transplant-boosts-immunotherapy-in-metastatic-renal-cell-carcinoma-in 2024-09-15T22:11:12+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fecal-microbiota-transplant-boosts-immunotherapy-in-metastatic-renal-cell-carcinoma-in 2024-09-15T22:11:12+00:00 weekly 0.7 https://trial.medpath.com/news/azn-imfinzi-regimen-reduces-death-risk-by-25-in-late-stage-muscle-invasive 2024-09-15T22:10:44+00:00 weekly 0.7 https://trial.medpath.com/zh/news/azn-imfinzi-regimen-reduces-death-risk-by-25-in-late-stage-muscle-invasive 2024-09-15T22:10:44+00:00 weekly 0.7 https://trial.medpath.com/news/dupixent-r-dupilumab-approved-in-the-u-s-as-first-and-only-treatment-for-adolescents 2024-09-15T21:30:57+00:00 weekly 0.7 https://trial.medpath.com/zh/news/dupixent-r-dupilumab-approved-in-the-u-s-as-first-and-only-treatment-for-adolescents 2024-09-15T21:30:57+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-lilly-s-ebglysstm-lebrikizumab-lbkz-for-adults-and-children-12-years-and 2024-09-15T21:14:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-lilly-s-ebglysstm-lebrikizumab-lbkz-for-adults-and-children-12-years-and 2024-09-15T21:14:56+00:00 weekly 0.7 https://trial.medpath.com/news/torl-1-23-generates-responses-in-heavily-pretreated-cldn6-positive-solid-tumors 2024-09-15T21:07:27+00:00 weekly 0.7 https://trial.medpath.com/zh/news/torl-1-23-generates-responses-in-heavily-pretreated-cldn6-positive-solid-tumors 2024-09-15T21:07:27+00:00 weekly 0.7 https://trial.medpath.com/news/liberty-cupid-study-c-confirms-benefit-of-dupilumab-in-biologic-naive-csu-hcplive 2024-09-15T21:07:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/liberty-cupid-study-c-confirms-benefit-of-dupilumab-in-biologic-naive-csu-hcplive 2024-09-15T21:07:01+00:00 weekly 0.7 https://trial.medpath.com/news/news-from-esmo-an-astrazeneca-win-in-bladder-cancer-and-more 2024-09-15T21:02:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/news-from-esmo-an-astrazeneca-win-in-bladder-cancer-and-more 2024-09-15T21:02:04+00:00 weekly 0.7 https://trial.medpath.com/news/car-t-cell-therapy-expands-beyond-cancer-new-frontiers-in-autoimmune-disease-treatment 2024-09-15T21:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/car-t-cell-therapy-expands-beyond-cancer-new-frontiers-in-autoimmune-disease-treatment 2024-09-15T21:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/ich-updates-guidelines-ngs-becomes-new-standard-for-viral-safety-testing-in-biotech-manufacturing 2024-09-15T21:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ich-updates-guidelines-ngs-becomes-new-standard-for-viral-safety-testing-in-biotech-manufacturing 2024-09-15T21:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/systems-thinking-approach-could-revolutionize-clinical-trial-success-rates 2024-09-15T21:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/systems-thinking-approach-could-revolutionize-clinical-trial-success-rates 2024-09-15T21:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/radionuclide-containing-combo-slows-metastatic-prostate-cancer-improves-survival 2024-09-15T20:25:14+00:00 weekly 0.7 https://trial.medpath.com/zh/news/radionuclide-containing-combo-slows-metastatic-prostate-cancer-improves-survival 2024-09-15T20:25:14+00:00 weekly 0.7 https://trial.medpath.com/news/cyramza-plus-lonsurf-did-not-improve-survival-in-metastatic-colorectal-cancer 2024-09-15T20:20:36+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cyramza-plus-lonsurf-did-not-improve-survival-in-metastatic-colorectal-cancer 2024-09-15T20:20:36+00:00 weekly 0.7 https://trial.medpath.com/news/new-covid-vaccines-may-be-coming-to-australia-here-s-what-to-know-about-the-jn-1-shots 2024-09-15T20:14:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-covid-vaccines-may-be-coming-to-australia-here-s-what-to-know-about-the-jn-1-shots 2024-09-15T20:14:39+00:00 weekly 0.7 https://trial.medpath.com/news/postsurgical-pembrolizumab-chemotherapy-misses-dfs-goal-in-endometrial-cancer 2024-09-15T20:12:49+00:00 weekly 0.7 https://trial.medpath.com/zh/news/postsurgical-pembrolizumab-chemotherapy-misses-dfs-goal-in-endometrial-cancer 2024-09-15T20:12:49+00:00 weekly 0.7 https://trial.medpath.com/news/advances-in-the-treatment-of-resectable-nsclc-key-insights-from-checkmate-77t 2024-09-15T20:12:02+00:00 weekly 0.7 https://trial.medpath.com/zh/news/advances-in-the-treatment-of-resectable-nsclc-key-insights-from-checkmate-77t 2024-09-15T20:12:02+00:00 weekly 0.7 https://trial.medpath.com/news/chemotherapy-de-escalation-associated-with-excellent-hr-her2-breast-cancer-survival 2024-09-15T19:35:38+00:00 weekly 0.7 https://trial.medpath.com/zh/news/chemotherapy-de-escalation-associated-with-excellent-hr-her2-breast-cancer-survival 2024-09-15T19:35:38+00:00 weekly 0.7 https://trial.medpath.com/news/splash-trial-highlights-radiopharmaceutical-lutetium-177-s-role-in-advanced-prostate 2024-09-15T19:32:48+00:00 weekly 0.7 https://trial.medpath.com/zh/news/splash-trial-highlights-radiopharmaceutical-lutetium-177-s-role-in-advanced-prostate 2024-09-15T19:32:48+00:00 weekly 0.7 https://trial.medpath.com/news/no-smoking-startup-s-tiny-answer-to-safer-medical-cannabis-nocamels 2024-09-15T19:22:24+00:00 weekly 0.7 https://trial.medpath.com/zh/news/no-smoking-startup-s-tiny-answer-to-safer-medical-cannabis-nocamels 2024-09-15T19:22:24+00:00 weekly 0.7 https://trial.medpath.com/news/lantheus-presents-results-from-the-primary-analysis-of-phase-3-pivotal-splash-trial-in 2024-09-15T19:13:53+00:00 weekly 0.7 https://trial.medpath.com/zh/news/lantheus-presents-results-from-the-primary-analysis-of-phase-3-pivotal-splash-trial-in 2024-09-15T19:13:53+00:00 weekly 0.7 https://trial.medpath.com/news/macrogenics-announces-updated-efficacy-safety-data-from-tamarack-phase-2-study 2024-09-15T19:12:49+00:00 weekly 0.7 https://trial.medpath.com/zh/news/macrogenics-announces-updated-efficacy-safety-data-from-tamarack-phase-2-study 2024-09-15T19:12:49+00:00 weekly 0.7 https://trial.medpath.com/news/akeso-published-first-ever-efficacy-data-for-pd-1-vegf-bispecific-antibody-ivonescimab 2024-09-15T19:10:53+00:00 weekly 0.7 https://trial.medpath.com/zh/news/akeso-published-first-ever-efficacy-data-for-pd-1-vegf-bispecific-antibody-ivonescimab 2024-09-15T19:10:53+00:00 weekly 0.7 https://trial.medpath.com/news/recent-health-headlines-fda-approvals-walgreens-settlement-and-more-devdiscourse 2024-09-15T19:03:36+00:00 weekly 0.7 https://trial.medpath.com/zh/news/recent-health-headlines-fda-approvals-walgreens-settlement-and-more-devdiscourse 2024-09-15T19:03:36+00:00 weekly 0.7 https://trial.medpath.com/news/retifanlimab-plus-carboplatin-and-paclitaxel-improve-pfs-in-recurrent-metastatic-anal-cancer 2024-09-15T19:02:29+00:00 weekly 0.7 https://trial.medpath.com/zh/news/retifanlimab-plus-carboplatin-and-paclitaxel-improve-pfs-in-recurrent-metastatic-anal-cancer 2024-09-15T19:02:29+00:00 weekly 0.7 https://trial.medpath.com/news/apple-s-airpods-pro-2-revolutionize-hearing-aid-tech-with-fda-approval 2024-09-15T19:02:03+00:00 weekly 0.7 https://trial.medpath.com/zh/news/apple-s-airpods-pro-2-revolutionize-hearing-aid-tech-with-fda-approval 2024-09-15T19:02:03+00:00 weekly 0.7 https://trial.medpath.com/news/atezolizumab-after-vemurafenib-and-cobimetinib-shows-trend-toward-better-os-in-melanoma 2024-09-15T18:59:33+00:00 weekly 0.7 https://trial.medpath.com/zh/news/atezolizumab-after-vemurafenib-and-cobimetinib-shows-trend-toward-better-os-in-melanoma 2024-09-15T18:59:33+00:00 weekly 0.7 https://trial.medpath.com/news/checkmate-77t-highlights-efs-benefit-in-perioperative-nivolumab-in-resectable-nsclc 2024-09-15T18:49:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/checkmate-77t-highlights-efs-benefit-in-perioperative-nivolumab-in-resectable-nsclc 2024-09-15T18:49:39+00:00 weekly 0.7 https://trial.medpath.com/news/icmr-formalises-moas-with-multiple-sponsors-under-phase-one-clinical-trials-network 2024-09-15T18:31:50+00:00 weekly 0.7 https://trial.medpath.com/zh/news/icmr-formalises-moas-with-multiple-sponsors-under-phase-one-clinical-trials-network 2024-09-15T18:31:50+00:00 weekly 0.7 https://trial.medpath.com/news/early-switch-therapy-to-atezolizumab-after-vemurafenib-cobimetinib-run-in-improves-os 2024-09-15T18:31:12+00:00 weekly 0.7 https://trial.medpath.com/zh/news/early-switch-therapy-to-atezolizumab-after-vemurafenib-cobimetinib-run-in-improves-os 2024-09-15T18:31:12+00:00 weekly 0.7 https://trial.medpath.com/news/extended-follow-up-shows-dfs-benefit-for-pembrolizumab-in-miuc-urology-times 2024-09-15T17:58:48+00:00 weekly 0.7 https://trial.medpath.com/zh/news/extended-follow-up-shows-dfs-benefit-for-pembrolizumab-in-miuc-urology-times 2024-09-15T17:58:48+00:00 weekly 0.7 https://trial.medpath.com/news/radiation-therapy-for-women-with-breast-cancer-will-now-last-for-no-more-than-three-weeks 2024-09-15T17:54:34+00:00 weekly 0.7 https://trial.medpath.com/zh/news/radiation-therapy-for-women-with-breast-cancer-will-now-last-for-no-more-than-three-weeks 2024-09-15T17:54:34+00:00 weekly 0.7 https://trial.medpath.com/news/missed-out-on-viking-therapeutics-buy-this-weight-loss-biotech-stock-right-now 2024-09-15T17:42:35+00:00 weekly 0.7 https://trial.medpath.com/zh/news/missed-out-on-viking-therapeutics-buy-this-weight-loss-biotech-stock-right-now 2024-09-15T17:42:35+00:00 weekly 0.7 https://trial.medpath.com/news/incremental-effectiveness-costs-may-improve-using-biomarker-guided-selection 2024-09-15T17:31:45+00:00 weekly 0.7 https://trial.medpath.com/zh/news/incremental-effectiveness-costs-may-improve-using-biomarker-guided-selection 2024-09-15T17:31:45+00:00 weekly 0.7 https://trial.medpath.com/news/os-increase-observed-in-neoadjuvant-pembrolizumab-combo-plus-adjuvant-therapy-in-early-tnbc 2024-09-15T17:29:33+00:00 weekly 0.7 https://trial.medpath.com/zh/news/os-increase-observed-in-neoadjuvant-pembrolizumab-combo-plus-adjuvant-therapy-in-early-tnbc 2024-09-15T17:29:33+00:00 weekly 0.7 https://trial.medpath.com/news/pembrolizumab-combo-shows-dfs-benefit-in-dmmr-endometrial-cancer-subgroup 2024-09-15T17:29:33+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pembrolizumab-combo-shows-dfs-benefit-in-dmmr-endometrial-cancer-subgroup 2024-09-15T17:29:33+00:00 weekly 0.7 https://trial.medpath.com/news/queen-mary-university-of-london-researchers-announce-ground-breaking-clinical-trial 2024-09-15T17:16:22+00:00 weekly 0.7 https://trial.medpath.com/zh/news/queen-mary-university-of-london-researchers-announce-ground-breaking-clinical-trial 2024-09-15T17:16:22+00:00 weekly 0.7 https://trial.medpath.com/news/neoadjuvant-pembrolizumab-chemo-adjuvant-pembrolizumab-boosts-os-in-early-tnbc 2024-09-15T17:12:08+00:00 weekly 0.7 https://trial.medpath.com/zh/news/neoadjuvant-pembrolizumab-chemo-adjuvant-pembrolizumab-boosts-os-in-early-tnbc 2024-09-15T17:12:08+00:00 weekly 0.7 https://trial.medpath.com/news/enhanced-progression-free-survival-with-retifanlimab-carboplatin-and-paclitaxel-in 2024-09-15T17:03:27+00:00 weekly 0.7 https://trial.medpath.com/zh/news/enhanced-progression-free-survival-with-retifanlimab-carboplatin-and-paclitaxel-in 2024-09-15T17:03:27+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approvals-fraud-settlements-and-global-health-initiatives-latest-health-news 2024-09-15T16:57:12+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approvals-fraud-settlements-and-global-health-initiatives-latest-health-news 2024-09-15T16:57:12+00:00 weekly 0.7 https://trial.medpath.com/news/doh-6-warns-public-on-unauthorized-mpox-vaccines-daily-guardian 2024-09-15T16:55:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/doh-6-warns-public-on-unauthorized-mpox-vaccines-daily-guardian 2024-09-15T16:55:56+00:00 weekly 0.7 https://trial.medpath.com/news/researchers-reveal-breakthrough-in-hard-to-treat-cancers-mirage-news 2024-09-15T16:49:22+00:00 weekly 0.7 https://trial.medpath.com/zh/news/researchers-reveal-breakthrough-in-hard-to-treat-cancers-mirage-news 2024-09-15T16:49:22+00:00 weekly 0.7 https://trial.medpath.com/news/queen-mary-university-of-london-researchers-announce-ground-breaking-trial-results-for 2024-09-15T16:48:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/queen-mary-university-of-london-researchers-announce-ground-breaking-trial-results-for 2024-09-15T16:48:00+00:00 weekly 0.7 https://trial.medpath.com/news/long-term-keynote-006-data-support-pembrolizumab-as-soc-in-advanced-melanoma 2024-09-15T16:35:03+00:00 weekly 0.7 https://trial.medpath.com/zh/news/long-term-keynote-006-data-support-pembrolizumab-as-soc-in-advanced-melanoma 2024-09-15T16:35:03+00:00 weekly 0.7 https://trial.medpath.com/news/olaparib-cediranib-misses-survival-end-points-in-relapsed-ovarian-cancer-trial-onclive 2024-09-15T16:22:34+00:00 weekly 0.7 https://trial.medpath.com/zh/news/olaparib-cediranib-misses-survival-end-points-in-relapsed-ovarian-cancer-trial-onclive 2024-09-15T16:22:34+00:00 weekly 0.7 https://trial.medpath.com/news/j-j-s-tar-200-phase-2b-sunrise-1-study-shows-84-complete-response-in-high-risk 2024-09-15T15:47:33+00:00 weekly 0.7 https://trial.medpath.com/zh/news/j-j-s-tar-200-phase-2b-sunrise-1-study-shows-84-complete-response-in-high-risk 2024-09-15T15:47:33+00:00 weekly 0.7 https://trial.medpath.com/news/esmo-2024-enhertu-to-eclipse-soc-for-her2-breast-cancer-with-brain-metastases 2024-09-15T15:23:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/esmo-2024-enhertu-to-eclipse-soc-for-her2-breast-cancer-with-brain-metastases 2024-09-15T15:23:01+00:00 weekly 0.7 https://trial.medpath.com/news/medilink-presents-yl201-b7h3-adc-at-esmo-2024-with-over-6-months-pfs-in-sclc 2024-09-15T15:16:54+00:00 weekly 0.7 https://trial.medpath.com/zh/news/medilink-presents-yl201-b7h3-adc-at-esmo-2024-with-over-6-months-pfs-in-sclc 2024-09-15T15:16:54+00:00 weekly 0.7 https://trial.medpath.com/news/neoadjuvant-immunotherapy-superior-to-targeted-therapy-in-stage-iii-melanoma 2024-09-15T15:10:18+00:00 weekly 0.7 https://trial.medpath.com/zh/news/neoadjuvant-immunotherapy-superior-to-targeted-therapy-in-stage-iii-melanoma 2024-09-15T15:10:18+00:00 weekly 0.7 https://trial.medpath.com/news/from-patient-to-entrepreneur-edmond-woman-creates-medical-device-kokh 2024-09-15T14:52:03+00:00 weekly 0.7 https://trial.medpath.com/zh/news/from-patient-to-entrepreneur-edmond-woman-creates-medical-device-kokh 2024-09-15T14:52:03+00:00 weekly 0.7 https://trial.medpath.com/news/esmo-gsk-iteos-bring-some-optimism-back-to-tigit-pharmaphorum 2024-09-15T14:46:55+00:00 weekly 0.7 https://trial.medpath.com/zh/news/esmo-gsk-iteos-bring-some-optimism-back-to-tigit-pharmaphorum 2024-09-15T14:46:55+00:00 weekly 0.7 https://trial.medpath.com/news/imfinzi-r-durvalumab-perioperative-regimen-reduced-the-risk-of-recurrence-by-32-and 2024-09-15T14:46:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/imfinzi-r-durvalumab-perioperative-regimen-reduced-the-risk-of-recurrence-by-32-and 2024-09-15T14:46:26+00:00 weekly 0.7 https://trial.medpath.com/news/imfinzi-r-durvalumab-perioperative-regimen-reduced-the-risk-of-recurrence-by-32-and 2024-09-15T14:44:41+00:00 weekly 0.7 https://trial.medpath.com/zh/news/imfinzi-r-durvalumab-perioperative-regimen-reduced-the-risk-of-recurrence-by-32-and 2024-09-15T14:44:41+00:00 weekly 0.7 https://trial.medpath.com/news/astrazeneca-s-imfinzi-increases-survival-rates-in-bladder-cancer-stat-news 2024-09-15T14:43:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/astrazeneca-s-imfinzi-increases-survival-rates-in-bladder-cancer-stat-news 2024-09-15T14:43:01+00:00 weekly 0.7 https://trial.medpath.com/news/esmo-2024-tecentriq-avastin-s-prospects-as-the-first-hcc-adjuvant-therapy-fade 2024-09-15T14:39:53+00:00 weekly 0.7 https://trial.medpath.com/zh/news/esmo-2024-tecentriq-avastin-s-prospects-as-the-first-hcc-adjuvant-therapy-fade 2024-09-15T14:39:53+00:00 weekly 0.7 https://trial.medpath.com/news/pfizer-presents-positive-data-from-phase-2-study-of-ponsegromab-in-patients-with-cancer-cachexia 2024-09-15T14:34:34+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pfizer-presents-positive-data-from-phase-2-study-of-ponsegromab-in-patients-with-cancer-cachexia 2024-09-15T14:34:34+00:00 weekly 0.7 https://trial.medpath.com/news/astrazeneca-s-imfinzi-increases-survival-rates-in-bladder-cancer-stat-news 2024-09-15T14:31:46+00:00 weekly 0.7 https://trial.medpath.com/zh/news/astrazeneca-s-imfinzi-increases-survival-rates-in-bladder-cancer-stat-news 2024-09-15T14:31:46+00:00 weekly 0.7 https://trial.medpath.com/news/roswell-park-designed-treatment-regimen-doubles-progression-free-survival-in 2024-09-15T14:25:59+00:00 weekly 0.7 https://trial.medpath.com/zh/news/roswell-park-designed-treatment-regimen-doubles-progression-free-survival-in 2024-09-15T14:25:59+00:00 weekly 0.7 https://trial.medpath.com/news/prince-trial-highlights-early-detection-of-prostate-cancer-progression-with-psma-pet-ct 2024-09-15T14:20:47+00:00 weekly 0.7 https://trial.medpath.com/zh/news/prince-trial-highlights-early-detection-of-prostate-cancer-progression-with-psma-pet-ct 2024-09-15T14:20:47+00:00 weekly 0.7 https://trial.medpath.com/news/disitamab-vedotin-promising-her2-targeted-therapy-for-urothelial-cancer-matthew-galsky 2024-09-15T14:14:46+00:00 weekly 0.7 https://trial.medpath.com/zh/news/disitamab-vedotin-promising-her2-targeted-therapy-for-urothelial-cancer-matthew-galsky 2024-09-15T14:14:46+00:00 weekly 0.7 https://trial.medpath.com/news/first-cancer-medicine-decision-following-pharmac-funding-boost-scoop-news 2024-09-15T14:10:40+00:00 weekly 0.7 https://trial.medpath.com/zh/news/first-cancer-medicine-decision-following-pharmac-funding-boost-scoop-news 2024-09-15T14:10:40+00:00 weekly 0.7 https://trial.medpath.com/news/3d-systems-smith-nephew-announce-fda-clearance-for-total-ankle-replacement-solution 2024-09-15T14:06:58+00:00 weekly 0.7 https://trial.medpath.com/zh/news/3d-systems-smith-nephew-announce-fda-clearance-for-total-ankle-replacement-solution 2024-09-15T14:06:58+00:00 weekly 0.7 https://trial.medpath.com/news/rybrevant-r-amivantamab-vmjw-plus-chemotherapy-show-49-percent-overall-response 2024-09-15T14:06:15+00:00 weekly 0.7 https://trial.medpath.com/zh/news/rybrevant-r-amivantamab-vmjw-plus-chemotherapy-show-49-percent-overall-response 2024-09-15T14:06:15+00:00 weekly 0.7 https://trial.medpath.com/news/weekend-icymi-september-9-to-september-13-drug-topics 2024-09-15T14:04:12+00:00 weekly 0.7 https://trial.medpath.com/zh/news/weekend-icymi-september-9-to-september-13-drug-topics 2024-09-15T14:04:12+00:00 weekly 0.7 https://trial.medpath.com/news/advances-in-the-treatment-of-resectable-nsclc-key-insights-from-checkmate-77t 2024-09-15T13:59:55+00:00 weekly 0.7 https://trial.medpath.com/zh/news/advances-in-the-treatment-of-resectable-nsclc-key-insights-from-checkmate-77t 2024-09-15T13:59:55+00:00 weekly 0.7 https://trial.medpath.com/news/dr-angeles-alvarez-secord-on-exciting-responses-with-mirvetuximab-soravtansine-in 2024-09-15T13:55:52+00:00 weekly 0.7 https://trial.medpath.com/zh/news/dr-angeles-alvarez-secord-on-exciting-responses-with-mirvetuximab-soravtansine-in 2024-09-15T13:55:52+00:00 weekly 0.7 https://trial.medpath.com/news/replimune-presents-primary-analysis-data-from-ignyte-globenewswire 2024-09-15T13:49:27+00:00 weekly 0.7 https://trial.medpath.com/zh/news/replimune-presents-primary-analysis-data-from-ignyte-globenewswire 2024-09-15T13:49:27+00:00 weekly 0.7 https://trial.medpath.com/news/high-dose-vitamin-d3-does-not-provide-benefit-for-metastatic-colorectal-cancer 2024-09-15T13:49:21+00:00 weekly 0.7 https://trial.medpath.com/zh/news/high-dose-vitamin-d3-does-not-provide-benefit-for-metastatic-colorectal-cancer 2024-09-15T13:49:21+00:00 weekly 0.7 https://trial.medpath.com/news/ambassador-trial-extended-follow-up-on-adjuvant-pembrolizumab-in-bladder-cancer 2024-09-15T13:38:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ambassador-trial-extended-follow-up-on-adjuvant-pembrolizumab-in-bladder-cancer 2024-09-15T13:38:39+00:00 weekly 0.7 https://trial.medpath.com/news/scorpion-therapeutics-presents-initial-clinical-data-from-its-phase-1-2-trial-of-stx-478-kxra 2024-09-15T13:32:38+00:00 weekly 0.7 https://trial.medpath.com/zh/news/scorpion-therapeutics-presents-initial-clinical-data-from-its-phase-1-2-trial-of-stx-478-kxra 2024-09-15T13:32:38+00:00 weekly 0.7 https://trial.medpath.com/news/the-dav132-colon-targeted-adsorbent-does-not-interfere-with-plasma-concentrations-of-nature 2024-09-15T13:31:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/the-dav132-colon-targeted-adsorbent-does-not-interfere-with-plasma-concentrations-of-nature 2024-09-15T13:31:00+00:00 weekly 0.7 https://trial.medpath.com/news/who-prequalifies-a-mpox-vaccine-clearing-path-to-access-contagion-live 2024-09-15T13:28:37+00:00 weekly 0.7 https://trial.medpath.com/zh/news/who-prequalifies-a-mpox-vaccine-clearing-path-to-access-contagion-live 2024-09-15T13:28:37+00:00 weekly 0.7 https://trial.medpath.com/news/macrogenics-announces-updated-efficacy-safety-data-from-tamarack-phase-2-study-of-vobra 2024-09-15T13:24:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/macrogenics-announces-updated-efficacy-safety-data-from-tamarack-phase-2-study-of-vobra 2024-09-15T13:24:30+00:00 weekly 0.7 https://trial.medpath.com/news/bristol-myers-squibb-presents-landmark-10-year-follow-up-data-from-checkmate-morningstar 2024-09-15T13:15:11+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bristol-myers-squibb-presents-landmark-10-year-follow-up-data-from-checkmate-morningstar 2024-09-15T13:15:11+00:00 weekly 0.7 https://trial.medpath.com/news/oncternal-therapeutics-axes-b-cell-lymphoma-trial-for-car-t-therapy-onct-808 2024-09-15T13:08:50+00:00 weekly 0.7 https://trial.medpath.com/zh/news/oncternal-therapeutics-axes-b-cell-lymphoma-trial-for-car-t-therapy-onct-808 2024-09-15T13:08:50+00:00 weekly 0.7 https://trial.medpath.com/news/apple-gets-fda-approval-for-airpods-pro-2-hearing-aid-feature-here-is-how-it-can-help-people 2024-09-15T13:01:23+00:00 weekly 0.7 https://trial.medpath.com/zh/news/apple-gets-fda-approval-for-airpods-pro-2-hearing-aid-feature-here-is-how-it-can-help-people 2024-09-15T13:01:23+00:00 weekly 0.7 https://trial.medpath.com/news/long-term-metastatic-melanoma-survival-dramatically-improves-on-immunotherapy-newsroom 2024-09-15T13:01:07+00:00 weekly 0.7 https://trial.medpath.com/zh/news/long-term-metastatic-melanoma-survival-dramatically-improves-on-immunotherapy-newsroom 2024-09-15T13:01:07+00:00 weekly 0.7 https://trial.medpath.com/news/investigational-rinatabart-sesutecan-rina-s-shows-promising-anti-tumor-activity-stock-titan 2024-09-15T12:59:29+00:00 weekly 0.7 https://trial.medpath.com/zh/news/investigational-rinatabart-sesutecan-rina-s-shows-promising-anti-tumor-activity-stock-titan 2024-09-15T12:59:29+00:00 weekly 0.7 https://trial.medpath.com/news/lantheus-presents-results-from-the-primary-analysis-of-phase-3-pivotal-splash-trial-in 2024-09-15T12:57:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/lantheus-presents-results-from-the-primary-analysis-of-phase-3-pivotal-splash-trial-in 2024-09-15T12:57:01+00:00 weekly 0.7 https://trial.medpath.com/news/investigational-rinatabart-sesutecan-rina-s-shows-promising-anti-tumor-yahoo-finance 2024-09-15T12:56:57+00:00 weekly 0.7 https://trial.medpath.com/zh/news/investigational-rinatabart-sesutecan-rina-s-shows-promising-anti-tumor-yahoo-finance 2024-09-15T12:56:57+00:00 weekly 0.7 https://trial.medpath.com/news/lantheus-presents-results-from-the-primary-analysis-of-phase-3-pivotal-splash-trial-in 2024-09-15T12:56:05+00:00 weekly 0.7 https://trial.medpath.com/zh/news/lantheus-presents-results-from-the-primary-analysis-of-phase-3-pivotal-splash-trial-in 2024-09-15T12:56:05+00:00 weekly 0.7 https://trial.medpath.com/news/long-term-metastatic-melanoma-survival-dramatically-improves-on-immunotherapy 2024-09-15T12:52:20+00:00 weekly 0.7 https://trial.medpath.com/zh/news/long-term-metastatic-melanoma-survival-dramatically-improves-on-immunotherapy 2024-09-15T12:52:20+00:00 weekly 0.7 https://trial.medpath.com/news/ipsen-provides-update-on-contact-02-phase-iii-trial-in-metastatic-castration-resistant 2024-09-15T12:52:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ipsen-provides-update-on-contact-02-phase-iii-trial-in-metastatic-castration-resistant 2024-09-15T12:52:13+00:00 weekly 0.7 https://trial.medpath.com/news/ten-year-data-for-merck-s-keytruda-r-pembrolizumab-demonstrates-sustained-overall 2024-09-15T12:50:32+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ten-year-data-for-merck-s-keytruda-r-pembrolizumab-demonstrates-sustained-overall 2024-09-15T12:50:32+00:00 weekly 0.7 https://trial.medpath.com/news/ds-9606-shows-promising-preliminary-clinical-activity-in-patients-with-advanced-solid-tumors 2024-09-15T12:50:12+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ds-9606-shows-promising-preliminary-clinical-activity-in-patients-with-advanced-solid-tumors 2024-09-15T12:50:12+00:00 weekly 0.7 https://trial.medpath.com/news/new-data-from-tar-200-phase-2b-sunrise-1-study-show-84-globenewswire 2024-09-15T12:39:20+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-data-from-tar-200-phase-2b-sunrise-1-study-show-84-globenewswire 2024-09-15T12:39:20+00:00 weekly 0.7 https://trial.medpath.com/news/new-data-from-tar-200-phase-2b-sunrise-1-study-show-84-percent-complete-response 2024-09-15T12:30:54+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-data-from-tar-200-phase-2b-sunrise-1-study-show-84-percent-complete-response 2024-09-15T12:30:54+00:00 weekly 0.7 https://trial.medpath.com/news/lenvatinib-pembrolizumab-and-tace-demonstrate-significant-progression-free-survival 2024-09-15T11:08:49+00:00 weekly 0.7 https://trial.medpath.com/zh/news/lenvatinib-pembrolizumab-and-tace-demonstrate-significant-progression-free-survival 2024-09-15T11:08:49+00:00 weekly 0.7 https://trial.medpath.com/news/targeted-pulse-quiz-september-15 2024-09-15T11:04:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/targeted-pulse-quiz-september-15 2024-09-15T11:04:17+00:00 weekly 0.7 https://trial.medpath.com/news/khcc-achieves-breakthrough-in-cancer-treatment-using-modified-t-lymphocytes 2024-09-15T10:31:48+00:00 weekly 0.7 https://trial.medpath.com/zh/news/khcc-achieves-breakthrough-in-cancer-treatment-using-modified-t-lymphocytes 2024-09-15T10:31:48+00:00 weekly 0.7 https://trial.medpath.com/news/retina-society-2024-advances-in-amd-therapy-highlight-different-mechanisms-of-action-with 2024-09-15T10:17:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/retina-society-2024-advances-in-amd-therapy-highlight-different-mechanisms-of-action-with 2024-09-15T10:17:30+00:00 weekly 0.7 https://trial.medpath.com/news/precede-biosciences-presents-new-data-at-esmo-2024-globenewswire 2024-09-15T10:07:14+00:00 weekly 0.7 https://trial.medpath.com/zh/news/precede-biosciences-presents-new-data-at-esmo-2024-globenewswire 2024-09-15T10:07:14+00:00 weekly 0.7 https://trial.medpath.com/news/no-survival-gain-with-preoperative-crt-plus-perioperative-chemo-for-gastric-cancer 2024-09-15T09:59:47+00:00 weekly 0.7 https://trial.medpath.com/zh/news/no-survival-gain-with-preoperative-crt-plus-perioperative-chemo-for-gastric-cancer 2024-09-15T09:59:47+00:00 weekly 0.7 https://trial.medpath.com/news/mayo-clinic-pharmacist-advocates-for-evidence-based-cannabis-discussions-in-cancer-care 2024-09-15T09:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/mayo-clinic-pharmacist-advocates-for-evidence-based-cannabis-discussions-in-cancer-care 2024-09-15T09:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/neoadjuvant-nivolumab-and-relatlimab-in-locally-advanced-mmr-deficient-colon-cancer 2024-09-15T07:45:33+00:00 weekly 0.7 https://trial.medpath.com/zh/news/neoadjuvant-nivolumab-and-relatlimab-in-locally-advanced-mmr-deficient-colon-cancer 2024-09-15T07:45:33+00:00 weekly 0.7 https://trial.medpath.com/news/23andme-therapeutics-announces-phase-2-results-for-two-additional-cancer-cohorts-and 2024-09-15T07:25:18+00:00 weekly 0.7 https://trial.medpath.com/zh/news/23andme-therapeutics-announces-phase-2-results-for-two-additional-cancer-cohorts-and 2024-09-15T07:25:18+00:00 weekly 0.7 https://trial.medpath.com/news/nhs-chiefs-to-roll-out-new-drugs-for-lethal-lung-disease-that-took-life-of-star-trek-actor 2024-09-15T05:48:55+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nhs-chiefs-to-roll-out-new-drugs-for-lethal-lung-disease-that-took-life-of-star-trek-actor 2024-09-15T05:48:55+00:00 weekly 0.7 https://trial.medpath.com/news/study-reveals-quality-gap-in-online-psoriasis-treatment-information-sources 2024-09-15T05:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/study-reveals-quality-gap-in-online-psoriasis-treatment-information-sources 2024-09-15T05:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/retina-society-2024-first-time-phase-2-clinical-trial-results-for-onl-1204-for 2024-09-15T04:10:08+00:00 weekly 0.7 https://trial.medpath.com/zh/news/retina-society-2024-first-time-phase-2-clinical-trial-results-for-onl-1204-for 2024-09-15T04:10:08+00:00 weekly 0.7 https://trial.medpath.com/news/breakthrough-as-scientists-develop-cancer-killing-treatment-that-preserves-healthy-body-cells 2024-09-15T01:07:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/breakthrough-as-scientists-develop-cancer-killing-treatment-that-preserves-healthy-body-cells 2024-09-15T01:07:39+00:00 weekly 0.7 https://trial.medpath.com/news/novel-agents-and-promising-combinations-in-urothelial-and-renal-cell-carcinoma-urotoday 2024-09-15T00:51:27+00:00 weekly 0.7 https://trial.medpath.com/zh/news/novel-agents-and-promising-combinations-in-urothelial-and-renal-cell-carcinoma-urotoday 2024-09-15T00:51:27+00:00 weekly 0.7 https://trial.medpath.com/news/clinical-trial-shows-promise-for-maralixibat-in-treating-algs-related-cholestatic-pruritus 2024-09-15T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/clinical-trial-shows-promise-for-maralixibat-in-treating-algs-related-cholestatic-pruritus 2024-09-15T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/esmo-2024-dr-jonasch-on-implications-of-positive-hif-2a-inhibitor-data-in-ccrcc 2024-09-14T23:10:34+00:00 weekly 0.7 https://trial.medpath.com/zh/news/esmo-2024-dr-jonasch-on-implications-of-positive-hif-2a-inhibitor-data-in-ccrcc 2024-09-14T23:10:34+00:00 weekly 0.7 https://trial.medpath.com/news/real-world-study-shows-comparable-outcomes-between-ct-p13-remicade-in-ra 2024-09-14T23:03:21+00:00 weekly 0.7 https://trial.medpath.com/zh/news/real-world-study-shows-comparable-outcomes-between-ct-p13-remicade-in-ra 2024-09-14T23:03:21+00:00 weekly 0.7 https://trial.medpath.com/news/gan-lee-pharmaceuticals-presented-two-positive-clinical-results-of-once-weekly-insulin 2024-09-14T23:00:58+00:00 weekly 0.7 https://trial.medpath.com/zh/news/gan-lee-pharmaceuticals-presented-two-positive-clinical-results-of-once-weekly-insulin 2024-09-14T23:00:58+00:00 weekly 0.7 https://trial.medpath.com/news/ipilimumab-nivolumab-significantly-improves-12-month-nccrcc-survival-in-sunniforecast 2024-09-14T22:01:40+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ipilimumab-nivolumab-significantly-improves-12-month-nccrcc-survival-in-sunniforecast 2024-09-14T22:01:40+00:00 weekly 0.7 https://trial.medpath.com/news/innovative-heart-valve-technology-could-improve-patient-lives-news-medical 2024-09-14T21:50:12+00:00 weekly 0.7 https://trial.medpath.com/zh/news/innovative-heart-valve-technology-could-improve-patient-lives-news-medical 2024-09-14T21:50:12+00:00 weekly 0.7 https://trial.medpath.com/news/enfortumab-vedotin-effective-in-patients-with-urothelial-cancer-outside-of-clinical-trials 2024-09-14T21:26:59+00:00 weekly 0.7 https://trial.medpath.com/zh/news/enfortumab-vedotin-effective-in-patients-with-urothelial-cancer-outside-of-clinical-trials 2024-09-14T21:26:59+00:00 weekly 0.7 https://trial.medpath.com/news/united-states-remote-climate-control-market-by-application-2024-2031-third-eye-news 2024-09-14T21:17:36+00:00 weekly 0.7 https://trial.medpath.com/zh/news/united-states-remote-climate-control-market-by-application-2024-2031-third-eye-news 2024-09-14T21:17:36+00:00 weekly 0.7 https://trial.medpath.com/news/andrea-banty-np-dnp-navigating-new-developments-in-ibd-therapeutics-hcplive 2024-09-14T21:15:08+00:00 weekly 0.7 https://trial.medpath.com/zh/news/andrea-banty-np-dnp-navigating-new-developments-in-ibd-therapeutics-hcplive 2024-09-14T21:15:08+00:00 weekly 0.7 https://trial.medpath.com/news/cancer-test-firm-oncologica-looking-to-raise-cash-this-is-money 2024-09-14T20:56:52+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cancer-test-firm-oncologica-looking-to-raise-cash-this-is-money 2024-09-14T20:56:52+00:00 weekly 0.7 https://trial.medpath.com/news/retifanlimab-plus-carboplatin-meets-pfs-end-point-in-metastatic-scac-cancer-network 2024-09-14T20:31:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/retifanlimab-plus-carboplatin-meets-pfs-end-point-in-metastatic-scac-cancer-network 2024-09-14T20:31:39+00:00 weekly 0.7 https://trial.medpath.com/news/addition-of-radium-223-to-enzalutamide-significantly-improves-rpfs-and-os-in-mcrpc 2024-09-14T20:18:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/addition-of-radium-223-to-enzalutamide-significantly-improves-rpfs-and-os-in-mcrpc 2024-09-14T20:18:04+00:00 weekly 0.7 https://trial.medpath.com/news/safety-activity-seen-with-frontline-zanidatamab-plus-chemo-bevacizumab-in-her2-mcrc 2024-09-14T20:04:59+00:00 weekly 0.7 https://trial.medpath.com/zh/news/safety-activity-seen-with-frontline-zanidatamab-plus-chemo-bevacizumab-in-her2-mcrc 2024-09-14T20:04:59+00:00 weekly 0.7 https://trial.medpath.com/news/diabetes-drug-may-lower-death-rate-in-obese-people-study-the-hindu 2024-09-14T20:00:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/diabetes-drug-may-lower-death-rate-in-obese-people-study-the-hindu 2024-09-14T20:00:17+00:00 weekly 0.7 https://trial.medpath.com/news/zipalertinib-shows-promise-in-heavily-pretreated-egfr-exon-20-mutated-nsclc 2024-09-14T19:23:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/zipalertinib-shows-promise-in-heavily-pretreated-egfr-exon-20-mutated-nsclc 2024-09-14T19:23:56+00:00 weekly 0.7 https://trial.medpath.com/news/adjuvant-pembrolizumab-chemotherapy-fails-to-improve-dfs-high-risk-endometrial-cancer 2024-09-14T19:03:25+00:00 weekly 0.7 https://trial.medpath.com/zh/news/adjuvant-pembrolizumab-chemotherapy-fails-to-improve-dfs-high-risk-endometrial-cancer 2024-09-14T19:03:25+00:00 weekly 0.7 https://trial.medpath.com/news/first-of-its-kind-colorectal-cancer-data-from-prospective-galaxy-study-released-at-esmo 2024-09-14T18:31:58+00:00 weekly 0.7 https://trial.medpath.com/zh/news/first-of-its-kind-colorectal-cancer-data-from-prospective-galaxy-study-released-at-esmo 2024-09-14T18:31:58+00:00 weekly 0.7 https://trial.medpath.com/news/encorafenib-binimetinib-exhibits-anti-tumor-activity-in-untreated-braf-mutant-advanced-nsclc 2024-09-14T18:24:44+00:00 weekly 0.7 https://trial.medpath.com/zh/news/encorafenib-binimetinib-exhibits-anti-tumor-activity-in-untreated-braf-mutant-advanced-nsclc 2024-09-14T18:24:44+00:00 weekly 0.7 https://trial.medpath.com/news/neoadjuvant-dato-dxd-plus-durvalumab-shows-variable-pcr-rates-in-stage-ii-iii-breast-cancer 2024-09-14T18:07:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/neoadjuvant-dato-dxd-plus-durvalumab-shows-variable-pcr-rates-in-stage-ii-iii-breast-cancer 2024-09-14T18:07:56+00:00 weekly 0.7 https://trial.medpath.com/news/esmo-2024-invited-discussant-optimizing-post-io-therapy-in-clear-cell-rcc-and 2024-09-14T17:41:31+00:00 weekly 0.7 https://trial.medpath.com/zh/news/esmo-2024-invited-discussant-optimizing-post-io-therapy-in-clear-cell-rcc-and 2024-09-14T17:41:31+00:00 weekly 0.7 https://trial.medpath.com/news/bristol-myers-squibb-s-karxt-faces-fda-approval-hurdles-analyst-issues-sell-rating-amid 2024-09-14T17:26:42+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bristol-myers-squibb-s-karxt-faces-fda-approval-hurdles-analyst-issues-sell-rating-amid 2024-09-14T17:26:42+00:00 weekly 0.7 https://trial.medpath.com/news/first-line-t-dxd-combinations-show-early-antitumor-activity-in-her2-gastric-gej-cancers 2024-09-14T17:09:31+00:00 weekly 0.7 https://trial.medpath.com/zh/news/first-line-t-dxd-combinations-show-early-antitumor-activity-in-her2-gastric-gej-cancers 2024-09-14T17:09:31+00:00 weekly 0.7 https://trial.medpath.com/news/study-ev-103-dose-escalation-cohort-a-5y-follow-up-of-first-line-enfortumab-vedotin 2024-09-14T16:53:10+00:00 weekly 0.7 https://trial.medpath.com/zh/news/study-ev-103-dose-escalation-cohort-a-5y-follow-up-of-first-line-enfortumab-vedotin 2024-09-14T16:53:10+00:00 weekly 0.7 https://trial.medpath.com/news/tigit-drug-from-iteos-shrinks-lung-tumors-in-trial-biopharma-dive 2024-09-14T16:51:27+00:00 weekly 0.7 https://trial.medpath.com/zh/news/tigit-drug-from-iteos-shrinks-lung-tumors-in-trial-biopharma-dive 2024-09-14T16:51:27+00:00 weekly 0.7 https://trial.medpath.com/news/rybrevant-shows-colorectal-cancer-promise-in-latest-bispecifics-win-biocentury 2024-09-14T16:46:43+00:00 weekly 0.7 https://trial.medpath.com/zh/news/rybrevant-shows-colorectal-cancer-promise-in-latest-bispecifics-win-biocentury 2024-09-14T16:46:43+00:00 weekly 0.7 https://trial.medpath.com/news/effect-of-aortic-valve-replacement-on-myocardial-perfusion-and-exercise-capacity-in-patients 2024-09-14T16:39:21+00:00 weekly 0.7 https://trial.medpath.com/zh/news/effect-of-aortic-valve-replacement-on-myocardial-perfusion-and-exercise-capacity-in-patients 2024-09-14T16:39:21+00:00 weekly 0.7 https://trial.medpath.com/news/data-support-pembrolizumab-regimen-as-new-standard-for-advanced-cervical-cancer 2024-09-14T16:39:07+00:00 weekly 0.7 https://trial.medpath.com/zh/news/data-support-pembrolizumab-regimen-as-new-standard-for-advanced-cervical-cancer 2024-09-14T16:39:07+00:00 weekly 0.7 https://trial.medpath.com/news/colorado-researcher-says-people-with-ptsd-are-losing-out-on-an-effective-treatment 2024-09-14T16:02:27+00:00 weekly 0.7 https://trial.medpath.com/zh/news/colorado-researcher-says-people-with-ptsd-are-losing-out-on-an-effective-treatment 2024-09-14T16:02:27+00:00 weekly 0.7 https://trial.medpath.com/news/bl-b01d1-shows-favorable-phase-2-efficacy-safety-for-urothelial-carcinoma-urology-times 2024-09-14T15:01:14+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bl-b01d1-shows-favorable-phase-2-efficacy-safety-for-urothelial-carcinoma-urology-times 2024-09-14T15:01:14+00:00 weekly 0.7 https://trial.medpath.com/news/checkpoint-inhibitor-staves-off-disease-progression-in-anal-cancer-trial-stat-news 2024-09-14T14:48:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/checkpoint-inhibitor-staves-off-disease-progression-in-anal-cancer-trial-stat-news 2024-09-14T14:48:00+00:00 weekly 0.7 https://trial.medpath.com/news/keytruda-r-pembrolizumab-plus-lenvima-r-lenvatinib-in-combination-with 2024-09-14T14:39:28+00:00 weekly 0.7 https://trial.medpath.com/zh/news/keytruda-r-pembrolizumab-plus-lenvima-r-lenvatinib-in-combination-with 2024-09-14T14:39:28+00:00 weekly 0.7 https://trial.medpath.com/news/merck-s-keytruda-r-pembrolizumab-plus-chemoradiotherapy-crt-reduced-risk-of 2024-09-14T14:33:34+00:00 weekly 0.7 https://trial.medpath.com/zh/news/merck-s-keytruda-r-pembrolizumab-plus-chemoradiotherapy-crt-reduced-risk-of 2024-09-14T14:33:34+00:00 weekly 0.7 https://trial.medpath.com/news/niktimvo-for-the-treatment-of-cgvhd-us-clinical-trials-arena 2024-09-14T14:16:20+00:00 weekly 0.7 https://trial.medpath.com/zh/news/niktimvo-for-the-treatment-of-cgvhd-us-clinical-trials-arena 2024-09-14T14:16:20+00:00 weekly 0.7 https://trial.medpath.com/news/pfizer-presents-positive-data-from-phase-2-study-of-ponsegromab-in-patients-with-cancer-cachexia 2024-09-14T13:40:20+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pfizer-presents-positive-data-from-phase-2-study-of-ponsegromab-in-patients-with-cancer-cachexia 2024-09-14T13:40:20+00:00 weekly 0.7 https://trial.medpath.com/news/company-statement-on-fda-advisory-committee-meeting-biospace 2024-09-14T13:14:52+00:00 weekly 0.7 https://trial.medpath.com/zh/news/company-statement-on-fda-advisory-committee-meeting-biospace 2024-09-14T13:14:52+00:00 weekly 0.7 https://trial.medpath.com/news/icmr-to-advance-1st-in-human-trials-for-zika-flu-blood-cancer-therapies-health-news 2024-09-14T12:38:54+00:00 weekly 0.7 https://trial.medpath.com/zh/news/icmr-to-advance-1st-in-human-trials-for-zika-flu-blood-cancer-therapies-health-news 2024-09-14T12:38:54+00:00 weekly 0.7 https://trial.medpath.com/news/gut-microbiome-emerges-as-key-player-in-cancer-immunotherapy-response-new-research-shows 2024-09-14T12:35:11+00:00 weekly 0.7 https://trial.medpath.com/zh/news/gut-microbiome-emerges-as-key-player-in-cancer-immunotherapy-response-new-research-shows 2024-09-14T12:35:11+00:00 weekly 0.7 https://trial.medpath.com/news/maui-derm-np-pa-fall-2024-conference-to-spotlight-latest-advances-in-dermatology-treatment 2024-09-14T12:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/maui-derm-np-pa-fall-2024-conference-to-spotlight-latest-advances-in-dermatology-treatment 2024-09-14T12:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/dr-jonathan-riess-on-the-potential-of-io102-io103-the-cancer-vaccine-landscape 2024-09-14T11:37:51+00:00 weekly 0.7 https://trial.medpath.com/zh/news/dr-jonathan-riess-on-the-potential-of-io102-io103-the-cancer-vaccine-landscape 2024-09-14T11:37:51+00:00 weekly 0.7 https://trial.medpath.com/news/esmo-2024-new-leadership-and-groundbreaking-developments-in-oncology-research-and-patient-care 2024-09-14T11:17:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/esmo-2024-new-leadership-and-groundbreaking-developments-in-oncology-research-and-patient-care 2024-09-14T11:17:39+00:00 weekly 0.7 https://trial.medpath.com/news/experts-highlight-new-dermatological-treatments-importance-of-clinical-trial-diversity 2024-09-14T11:06:45+00:00 weekly 0.7 https://trial.medpath.com/zh/news/experts-highlight-new-dermatological-treatments-importance-of-clinical-trial-diversity 2024-09-14T11:06:45+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-new-alzheimer-s-drug-to-slow-disease-progression-nbc26 2024-09-14T10:59:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-new-alzheimer-s-drug-to-slow-disease-progression-nbc26 2024-09-14T10:59:56+00:00 weekly 0.7 https://trial.medpath.com/news/what-happened-in-optometry-this-week-september-9 2024-09-14T10:30:57+00:00 weekly 0.7 https://trial.medpath.com/zh/news/what-happened-in-optometry-this-week-september-9 2024-09-14T10:30:57+00:00 weekly 0.7 https://trial.medpath.com/news/ocudyne-completes-successful-pilot-study-of-optic-system-ophthalmology-times 2024-09-14T10:18:11+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ocudyne-completes-successful-pilot-study-of-optic-system-ophthalmology-times 2024-09-14T10:18:11+00:00 weekly 0.7 https://trial.medpath.com/news/correction-to-eli-lilly-gets-fda-approval-for-eczema-treatment-article-morningstar 2024-09-14T10:15:19+00:00 weekly 0.7 https://trial.medpath.com/zh/news/correction-to-eli-lilly-gets-fda-approval-for-eczema-treatment-article-morningstar 2024-09-14T10:15:19+00:00 weekly 0.7 https://trial.medpath.com/news/less-toxic-cancer-therapies-for-healthier-lives-featured-research-seattle-children-s 2024-09-14T09:45:52+00:00 weekly 0.7 https://trial.medpath.com/zh/news/less-toxic-cancer-therapies-for-healthier-lives-featured-research-seattle-children-s 2024-09-14T09:45:52+00:00 weekly 0.7 https://trial.medpath.com/news/fda-updates-warning-for-liver-injury-due-to-fezolinetant-contemporary-ob-gyn 2024-09-14T09:23:50+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-updates-warning-for-liver-injury-due-to-fezolinetant-contemporary-ob-gyn 2024-09-14T09:23:50+00:00 weekly 0.7 https://trial.medpath.com/news/nuvation-bio-announces-positive-pooled-data-from-the-pivotal-phase-2-trust-i-marketscreener 2024-09-14T08:11:21+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nuvation-bio-announces-positive-pooled-data-from-the-pivotal-phase-2-trust-i-marketscreener 2024-09-14T08:11:21+00:00 weekly 0.7 https://trial.medpath.com/news/car-t-reduces-all-cause-mortality-greater-than-a-bispecific-antibody-in-mm 2024-09-14T08:09:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/car-t-reduces-all-cause-mortality-greater-than-a-bispecific-antibody-in-mm 2024-09-14T08:09:17+00:00 weekly 0.7 https://trial.medpath.com/news/immunocore-holdings-plc-american-depositary-shares-imcr-stock-news 2024-09-14T08:03:18+00:00 weekly 0.7 https://trial.medpath.com/zh/news/immunocore-holdings-plc-american-depositary-shares-imcr-stock-news 2024-09-14T08:03:18+00:00 weekly 0.7 https://trial.medpath.com/news/sutro-biopharma-announces-updated-data-from-phase-1b-study-of-luvelta-in-combination 2024-09-14T07:46:58+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sutro-biopharma-announces-updated-data-from-phase-1b-study-of-luvelta-in-combination 2024-09-14T07:46:58+00:00 weekly 0.7 https://trial.medpath.com/news/acrivon-therapeutics-reports-positive-endometrial-cancer-data-from-ongoing-acr-368 2024-09-14T07:20:57+00:00 weekly 0.7 https://trial.medpath.com/zh/news/acrivon-therapeutics-reports-positive-endometrial-cancer-data-from-ongoing-acr-368 2024-09-14T07:20:57+00:00 weekly 0.7 https://trial.medpath.com/news/neurologylive-r-friday-5-september-13-2024 2024-09-14T07:05:10+00:00 weekly 0.7 https://trial.medpath.com/zh/news/neurologylive-r-friday-5-september-13-2024 2024-09-14T07:05:10+00:00 weekly 0.7 https://trial.medpath.com/news/repare-therapeutics-to-present-data-from-phase-1-2-tresr-clinical-trial-evaluating-biospace 2024-09-14T06:54:29+00:00 weekly 0.7 https://trial.medpath.com/zh/news/repare-therapeutics-to-present-data-from-phase-1-2-tresr-clinical-trial-evaluating-biospace 2024-09-14T06:54:29+00:00 weekly 0.7 https://trial.medpath.com/news/prelude-therapeutics-smarca2-degrader-prt3789-demonstrated-promising-initial-biospace 2024-09-14T06:54:03+00:00 weekly 0.7 https://trial.medpath.com/zh/news/prelude-therapeutics-smarca2-degrader-prt3789-demonstrated-promising-initial-biospace 2024-09-14T06:54:03+00:00 weekly 0.7 https://trial.medpath.com/news/bms-immunotherapy-hits-in-lung-cancer-advancing-to-phase-3-stat-news 2024-09-14T06:53:07+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bms-immunotherapy-hits-in-lung-cancer-advancing-to-phase-3-stat-news 2024-09-14T06:53:07+00:00 weekly 0.7 https://trial.medpath.com/news/oneoncology-cmo-highlights-critical-role-of-real-world-evidence-in-precision-medicine-testing 2024-09-14T06:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/oneoncology-cmo-highlights-critical-role-of-real-world-evidence-in-precision-medicine-testing 2024-09-14T06:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/oncternal-stock-crashes-by-60-as-it-lays-off-staff-and-scraps-trials 2024-09-14T05:46:41+00:00 weekly 0.7 https://trial.medpath.com/zh/news/oncternal-stock-crashes-by-60-as-it-lays-off-staff-and-scraps-trials 2024-09-14T05:46:41+00:00 weekly 0.7 https://trial.medpath.com/news/frontline-bms-986012-plus-nivolumab-chemotherapy-shows-promise-in-es-sclc 2024-09-14T05:08:43+00:00 weekly 0.7 https://trial.medpath.com/zh/news/frontline-bms-986012-plus-nivolumab-chemotherapy-shows-promise-in-es-sclc 2024-09-14T05:08:43+00:00 weekly 0.7 https://trial.medpath.com/news/nutrition-remains-critical-in-mash-management-despite-new-drug-approval-experts-emphasize 2024-09-14T04:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nutrition-remains-critical-in-mash-management-despite-new-drug-approval-experts-emphasize 2024-09-14T04:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-lilly-s-ebglysstm-lebrikizumab-lbkz-for-adults-and-children-12-years-and 2024-09-14T00:33:25+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-lilly-s-ebglysstm-lebrikizumab-lbkz-for-adults-and-children-12-years-and 2024-09-14T00:33:25+00:00 weekly 0.7 https://trial.medpath.com/news/3-biotech-ipos-703m-raised-for-clinical-trials-in-cancer-immunology-endocrine-disorders 2024-09-14T00:30:29+00:00 weekly 0.7 https://trial.medpath.com/zh/news/3-biotech-ipos-703m-raised-for-clinical-trials-in-cancer-immunology-endocrine-disorders 2024-09-14T00:30:29+00:00 weekly 0.7 https://trial.medpath.com/news/japan-s-ministry-of-health-labor-and-welfare-approves-csl-and-arcturus-therapeutics 2024-09-14T00:16:23+00:00 weekly 0.7 https://trial.medpath.com/zh/news/japan-s-ministry-of-health-labor-and-welfare-approves-csl-and-arcturus-therapeutics 2024-09-14T00:16:23+00:00 weekly 0.7 https://trial.medpath.com/news/belzutifan-yields-sustained-responses-pfs-in-advanced-clear-cell-rcc-cancer-network 2024-09-14T00:08:55+00:00 weekly 0.7 https://trial.medpath.com/zh/news/belzutifan-yields-sustained-responses-pfs-in-advanced-clear-cell-rcc-cancer-network 2024-09-14T00:08:55+00:00 weekly 0.7 https://trial.medpath.com/news/digital-medicine-support-models-tested-for-alcohol-use-disorder 2024-09-14T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/digital-medicine-support-models-tested-for-alcohol-use-disorder 2024-09-14T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/how-to-optimise-treatment-in-egfr-mutant-nsclc 2024-09-14T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/how-to-optimise-treatment-in-egfr-mutant-nsclc 2024-09-14T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/darolutamide-in-addition-to-adt-versus-adt-in-metastatic-hormone-sensitive-prostate-urotoday 2024-09-13T23:07:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/darolutamide-in-addition-to-adt-versus-adt-in-metastatic-hormone-sensitive-prostate-urotoday 2024-09-13T23:07:56+00:00 weekly 0.7 https://trial.medpath.com/news/gadgeel-s-preview-of-key-esmo-2024-findings-in-lung-cancer-targeted-oncology 2024-09-13T23:03:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/gadgeel-s-preview-of-key-esmo-2024-findings-in-lung-cancer-targeted-oncology 2024-09-13T23:03:56+00:00 weekly 0.7 https://trial.medpath.com/news/adjuvant-durvalumab-fails-to-boost-dfs-in-resected-nsclc-irrespective-of-pd-l1-status 2024-09-13T21:31:47+00:00 weekly 0.7 https://trial.medpath.com/zh/news/adjuvant-durvalumab-fails-to-boost-dfs-in-resected-nsclc-irrespective-of-pd-l1-status 2024-09-13T21:31:47+00:00 weekly 0.7 https://trial.medpath.com/news/subcutaneous-tecentriq-gets-fda-ok-gilead-shot-succeeds-in-second-hiv-trial 2024-09-13T21:28:49+00:00 weekly 0.7 https://trial.medpath.com/zh/news/subcutaneous-tecentriq-gets-fda-ok-gilead-shot-succeeds-in-second-hiv-trial 2024-09-13T21:28:49+00:00 weekly 0.7 https://trial.medpath.com/news/essa-pharma-presents-updated-phase-1-2-masofaniten-epi-7386-clinical-data-at-the 2024-09-13T21:21:52+00:00 weekly 0.7 https://trial.medpath.com/zh/news/essa-pharma-presents-updated-phase-1-2-masofaniten-epi-7386-clinical-data-at-the 2024-09-13T21:21:52+00:00 weekly 0.7 https://trial.medpath.com/news/beyond-celiac-accelerates-search-for-celiac-disease-cure-by-2030-benzinga 2024-09-13T21:19:33+00:00 weekly 0.7 https://trial.medpath.com/zh/news/beyond-celiac-accelerates-search-for-celiac-disease-cure-by-2030-benzinga 2024-09-13T21:19:33+00:00 weekly 0.7 https://trial.medpath.com/news/arizona-liver-health-arizona-clinical-trials-celebrates-the-grand-opening-of-act-medical-park 2024-09-13T20:20:31+00:00 weekly 0.7 https://trial.medpath.com/zh/news/arizona-liver-health-arizona-clinical-trials-celebrates-the-grand-opening-of-act-medical-park 2024-09-13T20:20:31+00:00 weekly 0.7 https://trial.medpath.com/news/a-pde4b-inhibitor-with-demonstrated-clinical-potential-in-treating-ipf 2024-09-13T20:14:16+00:00 weekly 0.7 https://trial.medpath.com/zh/news/a-pde4b-inhibitor-with-demonstrated-clinical-potential-in-treating-ipf 2024-09-13T20:14:16+00:00 weekly 0.7 https://trial.medpath.com/news/two-organizations-partner-to-develop-research-on-veterinary-device-for-osteoarthitis 2024-09-13T20:12:44+00:00 weekly 0.7 https://trial.medpath.com/zh/news/two-organizations-partner-to-develop-research-on-veterinary-device-for-osteoarthitis 2024-09-13T20:12:44+00:00 weekly 0.7 https://trial.medpath.com/news/mercks-irreversible-lsd1-inhibitor-for-mpns 2024-09-13T19:57:43+00:00 weekly 0.7 https://trial.medpath.com/zh/news/mercks-irreversible-lsd1-inhibitor-for-mpns 2024-09-13T19:57:43+00:00 weekly 0.7 https://trial.medpath.com/news/a-dual-5-ht2a-and-5-ht2c-receptor-inverse-agonist-developed-to-address-the-limitations-of-pimavanserin 2024-09-13T19:51:25+00:00 weekly 0.7 https://trial.medpath.com/zh/news/a-dual-5-ht2a-and-5-ht2c-receptor-inverse-agonist-developed-to-address-the-limitations-of-pimavanserin 2024-09-13T19:51:25+00:00 weekly 0.7 https://trial.medpath.com/news/consolidation-durvalumab-consistently-improves-pfs-os-in-ls-sclc-subgroups 2024-09-13T19:50:55+00:00 weekly 0.7 https://trial.medpath.com/zh/news/consolidation-durvalumab-consistently-improves-pfs-os-in-ls-sclc-subgroups 2024-09-13T19:50:55+00:00 weekly 0.7 https://trial.medpath.com/news/a-potent-zwitterionic-inhibitor-of-khk 2024-09-13T19:40:32+00:00 weekly 0.7 https://trial.medpath.com/zh/news/a-potent-zwitterionic-inhibitor-of-khk 2024-09-13T19:40:32+00:00 weekly 0.7 https://trial.medpath.com/news/tempus-announces-four-abstracts-accepted-for-presentation-at-the-european-society-biospace 2024-09-13T19:40:15+00:00 weekly 0.7 https://trial.medpath.com/zh/news/tempus-announces-four-abstracts-accepted-for-presentation-at-the-european-society-biospace 2024-09-13T19:40:15+00:00 weekly 0.7 https://trial.medpath.com/news/a-cbd-analogue-and-gpr55-antagonist-for-neuropathic-pain 2024-09-13T19:31:29+00:00 weekly 0.7 https://trial.medpath.com/zh/news/a-cbd-analogue-and-gpr55-antagonist-for-neuropathic-pain 2024-09-13T19:31:29+00:00 weekly 0.7 https://trial.medpath.com/news/press-releases-friday-sep-13-2024-genentech 2024-09-13T18:21:03+00:00 weekly 0.7 https://trial.medpath.com/zh/news/press-releases-friday-sep-13-2024-genentech 2024-09-13T18:21:03+00:00 weekly 0.7 https://trial.medpath.com/news/cabozantinib-nivolumab-combination-findings-further-inform-rcc-care-onclive 2024-09-13T18:03:03+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cabozantinib-nivolumab-combination-findings-further-inform-rcc-care-onclive 2024-09-13T18:03:03+00:00 weekly 0.7 https://trial.medpath.com/news/esmo-2024-a-new-medically-promising-antibody-conjugate-for-metastatic-breast-cancer 2024-09-13T17:59:38+00:00 weekly 0.7 https://trial.medpath.com/zh/news/esmo-2024-a-new-medically-promising-antibody-conjugate-for-metastatic-breast-cancer 2024-09-13T17:59:38+00:00 weekly 0.7 https://trial.medpath.com/news/tivozanib-monotherapy-bests-lower-dose-tivozanib-plus-nivolumab-in-metastatic-rcc-onclive 2024-09-13T17:54:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/tivozanib-monotherapy-bests-lower-dose-tivozanib-plus-nivolumab-in-metastatic-rcc-onclive 2024-09-13T17:54:01+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-subcutaneous-formulation-of-ocrelizumab-for-relapsing-and-progresive 2024-09-13T17:51:54+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-subcutaneous-formulation-of-ocrelizumab-for-relapsing-and-progresive 2024-09-13T17:51:54+00:00 weekly 0.7 https://trial.medpath.com/news/cidara-axes-30-of-staff-to-focus-on-flu-prevention-drug-pharmaceutical-technology 2024-09-13T17:46:59+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cidara-axes-30-of-staff-to-focus-on-flu-prevention-drug-pharmaceutical-technology 2024-09-13T17:46:59+00:00 weekly 0.7 https://trial.medpath.com/news/cipher-pharmaceuticals-partner-moberg-pharma-ab-provides-update-on-mob-015-phase-3-study 2024-09-13T17:38:25+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cipher-pharmaceuticals-partner-moberg-pharma-ab-provides-update-on-mob-015-phase-3-study 2024-09-13T17:38:25+00:00 weekly 0.7 https://trial.medpath.com/news/novel-adc-azd8205-demonstrates-manageable-safety-profile-and-preliminary-efficacy-in 2024-09-13T17:28:15+00:00 weekly 0.7 https://trial.medpath.com/zh/news/novel-adc-azd8205-demonstrates-manageable-safety-profile-and-preliminary-efficacy-in 2024-09-13T17:28:15+00:00 weekly 0.7 https://trial.medpath.com/news/inflammatix-raises-57m-to-advance-test-for-infection-sepsis-medtech-dive 2024-09-13T16:47:38+00:00 weekly 0.7 https://trial.medpath.com/zh/news/inflammatix-raises-57m-to-advance-test-for-infection-sepsis-medtech-dive 2024-09-13T16:47:38+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-dupilumab-for-adolescents-with-chronic-rhinosinusitis-with-nasal-polyps 2024-09-13T16:42:28+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-dupilumab-for-adolescents-with-chronic-rhinosinusitis-with-nasal-polyps 2024-09-13T16:42:28+00:00 weekly 0.7 https://trial.medpath.com/news/engineered-parasite-delivers-therapeutic-proteins-to-the-mouse-brain-nature-biotechnology 2024-09-13T16:11:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/engineered-parasite-delivers-therapeutic-proteins-to-the-mouse-brain-nature-biotechnology 2024-09-13T16:11:56+00:00 weekly 0.7 https://trial.medpath.com/news/new-guidance-helps-clinicians-use-pemivibart-to-protect-immunocompromised-patients 2024-09-13T16:01:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-guidance-helps-clinicians-use-pemivibart-to-protect-immunocompromised-patients 2024-09-13T16:01:00+00:00 weekly 0.7 https://trial.medpath.com/news/lenvatinib-pembrolizumab-combo-shows-promise-in-thymic-epithelial-tumors 2024-09-13T15:54:08+00:00 weekly 0.7 https://trial.medpath.com/zh/news/lenvatinib-pembrolizumab-combo-shows-promise-in-thymic-epithelial-tumors 2024-09-13T15:54:08+00:00 weekly 0.7 https://trial.medpath.com/news/essential-components-of-an-electronic-patient-reported-symptom-monitoring-and-jama-network 2024-09-13T15:36:28+00:00 weekly 0.7 https://trial.medpath.com/zh/news/essential-components-of-an-electronic-patient-reported-symptom-monitoring-and-jama-network 2024-09-13T15:36:28+00:00 weekly 0.7 https://trial.medpath.com/news/fixed-duration-vs-continuous-cll-therapy-balancing-efficacy-quality-of-life-and-costs 2024-09-13T15:14:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fixed-duration-vs-continuous-cll-therapy-balancing-efficacy-quality-of-life-and-costs 2024-09-13T15:14:13+00:00 weekly 0.7 https://trial.medpath.com/news/study-identifies-key-factors-for-long-term-weight-loss-with-glp-1-medications 2024-09-13T15:14:02+00:00 weekly 0.7 https://trial.medpath.com/zh/news/study-identifies-key-factors-for-long-term-weight-loss-with-glp-1-medications 2024-09-13T15:14:02+00:00 weekly 0.7 https://trial.medpath.com/news/antisense-oligonucleotide-vo659-reduces-mutant-huntingtin-protein-interim-phase-1-2-data-show 2024-09-13T15:12:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/antisense-oligonucleotide-vo659-reduces-mutant-huntingtin-protein-interim-phase-1-2-data-show 2024-09-13T15:12:39+00:00 weekly 0.7 https://trial.medpath.com/news/ozempic-or-saxenda-for-weight-loss-which-works-best 2024-09-13T15:09:49+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ozempic-or-saxenda-for-weight-loss-which-works-best 2024-09-13T15:09:49+00:00 weekly 0.7 https://trial.medpath.com/news/astrazeneca-launches-truqap-as-korea-s-1st-akt-inhibitor-for-breast-cancer-patients 2024-09-13T14:53:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/astrazeneca-launches-truqap-as-korea-s-1st-akt-inhibitor-for-breast-cancer-patients 2024-09-13T14:53:13+00:00 weekly 0.7 https://trial.medpath.com/news/inhaled-antibiotic-for-bronchiectasis-shows-benefit-and-then-it-doesn-t-medpage-today 2024-09-13T14:41:42+00:00 weekly 0.7 https://trial.medpath.com/zh/news/inhaled-antibiotic-for-bronchiectasis-shows-benefit-and-then-it-doesn-t-medpage-today 2024-09-13T14:41:42+00:00 weekly 0.7 https://trial.medpath.com/news/endo-presents-data-at-the-american-orthopaedic-foot-ankle-society-annual-meeting 2024-09-13T14:32:44+00:00 weekly 0.7 https://trial.medpath.com/zh/news/endo-presents-data-at-the-american-orthopaedic-foot-ankle-society-annual-meeting 2024-09-13T14:32:44+00:00 weekly 0.7 https://trial.medpath.com/news/representation-of-women-and-people-of-color-in-clinical-trials-is-crucial 2024-09-13T14:29:37+00:00 weekly 0.7 https://trial.medpath.com/zh/news/representation-of-women-and-people-of-color-in-clinical-trials-is-crucial 2024-09-13T14:29:37+00:00 weekly 0.7 https://trial.medpath.com/news/moderna-forecasts-lower-sales-next-year-shares-near-four-year-low-bilyonaryo 2024-09-13T14:27:44+00:00 weekly 0.7 https://trial.medpath.com/zh/news/moderna-forecasts-lower-sales-next-year-shares-near-four-year-low-bilyonaryo 2024-09-13T14:27:44+00:00 weekly 0.7 https://trial.medpath.com/news/antibody-drug-conjugate-found-effective-against-brain-metastases-in-patients-with-her2 2024-09-13T14:18:33+00:00 weekly 0.7 https://trial.medpath.com/zh/news/antibody-drug-conjugate-found-effective-against-brain-metastases-in-patients-with-her2 2024-09-13T14:18:33+00:00 weekly 0.7 https://trial.medpath.com/news/enhertu-showed-substantial-clinical-activity-in-patients-with-her2-positive-metastatic-breast 2024-09-13T14:09:40+00:00 weekly 0.7 https://trial.medpath.com/zh/news/enhertu-showed-substantial-clinical-activity-in-patients-with-her2-positive-metastatic-breast 2024-09-13T14:09:40+00:00 weekly 0.7 https://trial.medpath.com/news/oshkosh-defense-submits-phase-ii-proposal-for-rcv-program-asdnews 2024-09-13T13:59:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/oshkosh-defense-submits-phase-ii-proposal-for-rcv-program-asdnews 2024-09-13T13:59:13+00:00 weekly 0.7 https://trial.medpath.com/news/fda-roundup-apple-airpods-hearing-aids-tremfya-for-ulcerative-colitis-drug-topics 2024-09-13T13:51:07+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-roundup-apple-airpods-hearing-aids-tremfya-for-ulcerative-colitis-drug-topics 2024-09-13T13:51:07+00:00 weekly 0.7 https://trial.medpath.com/news/esmo-2024-new-hope-in-the-treatment-of-thymus-gland-cancers-gustave-roussy 2024-09-13T13:32:23+00:00 weekly 0.7 https://trial.medpath.com/zh/news/esmo-2024-new-hope-in-the-treatment-of-thymus-gland-cancers-gustave-roussy 2024-09-13T13:32:23+00:00 weekly 0.7 https://trial.medpath.com/news/oncology-leaders-highlight-challenges-in-managing-rapidly-evolving-cancer-treatment-data 2024-09-13T13:19:34+00:00 weekly 0.7 https://trial.medpath.com/zh/news/oncology-leaders-highlight-challenges-in-managing-rapidly-evolving-cancer-treatment-data 2024-09-13T13:19:34+00:00 weekly 0.7 https://trial.medpath.com/news/research-extends-hope-for-gastric-cancer-patients-with-peritoneal-metastasis 2024-09-13T13:12:02+00:00 weekly 0.7 https://trial.medpath.com/zh/news/research-extends-hope-for-gastric-cancer-patients-with-peritoneal-metastasis 2024-09-13T13:12:02+00:00 weekly 0.7 https://trial.medpath.com/news/can-glp-1-drugs-help-with-type-1-diabetes 2024-09-13T13:11:57+00:00 weekly 0.7 https://trial.medpath.com/zh/news/can-glp-1-drugs-help-with-type-1-diabetes 2024-09-13T13:11:57+00:00 weekly 0.7 https://trial.medpath.com/news/new-frontiers-in-technology-ai-use-in-clinical-trial-patient-recruitment-in-health-systems 2024-09-13T13:01:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-frontiers-in-technology-ai-use-in-clinical-trial-patient-recruitment-in-health-systems 2024-09-13T13:01:13+00:00 weekly 0.7 https://trial.medpath.com/news/amgen-to-present-data-from-multiple-early-stage-clinical-trials-at-esmo-2024 2024-09-13T13:00:40+00:00 weekly 0.7 https://trial.medpath.com/zh/news/amgen-to-present-data-from-multiple-early-stage-clinical-trials-at-esmo-2024 2024-09-13T13:00:40+00:00 weekly 0.7 https://trial.medpath.com/news/ascendis-to-present-first-results-from-platinum-resistant-ovarian-cancer-proc-cohort-of 2024-09-13T12:59:53+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ascendis-to-present-first-results-from-platinum-resistant-ovarian-cancer-proc-cohort-of 2024-09-13T12:59:53+00:00 weekly 0.7 https://trial.medpath.com/news/marengo-therapeutics-announces-clinical-study-collaboration-with-gilead-pr-newswire 2024-09-13T12:56:57+00:00 weekly 0.7 https://trial.medpath.com/zh/news/marengo-therapeutics-announces-clinical-study-collaboration-with-gilead-pr-newswire 2024-09-13T12:56:57+00:00 weekly 0.7 https://trial.medpath.com/news/depression-five-million-americans-may-benefit-from-psychedelic-therapy-newsweek 2024-09-13T12:30:36+00:00 weekly 0.7 https://trial.medpath.com/zh/news/depression-five-million-americans-may-benefit-from-psychedelic-therapy-newsweek 2024-09-13T12:30:36+00:00 weekly 0.7 https://trial.medpath.com/news/esmo-moderna-s-mrna-solid-tumour-vaccine-shows-early-promise-clinical-trials-arena 2024-09-13T12:27:53+00:00 weekly 0.7 https://trial.medpath.com/zh/news/esmo-moderna-s-mrna-solid-tumour-vaccine-shows-early-promise-clinical-trials-arena 2024-09-13T12:27:53+00:00 weekly 0.7 https://trial.medpath.com/news/atea-pharmaceuticals-provides-update-on-global-phase-3-sunrise-3-trial-evaluating 2024-09-13T12:26:48+00:00 weekly 0.7 https://trial.medpath.com/zh/news/atea-pharmaceuticals-provides-update-on-global-phase-3-sunrise-3-trial-evaluating 2024-09-13T12:26:48+00:00 weekly 0.7 https://trial.medpath.com/news/ira-implementation-reshapes-cancer-drug-development-and-patient-access-landscape 2024-09-13T12:11:20+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ira-implementation-reshapes-cancer-drug-development-and-patient-access-landscape 2024-09-13T12:11:20+00:00 weekly 0.7 https://trial.medpath.com/news/blenrep-belantamab-mafodotin-in-combination-receives-breakthrough-therapy-gsk 2024-09-13T12:06:25+00:00 weekly 0.7 https://trial.medpath.com/zh/news/blenrep-belantamab-mafodotin-in-combination-receives-breakthrough-therapy-gsk 2024-09-13T12:06:25+00:00 weekly 0.7 https://trial.medpath.com/news/psychedelic-therapeutics-clinical-trials-research-report-globenewswire 2024-09-13T10:58:33+00:00 weekly 0.7 https://trial.medpath.com/zh/news/psychedelic-therapeutics-clinical-trials-research-report-globenewswire 2024-09-13T10:58:33+00:00 weekly 0.7 https://trial.medpath.com/news/cooperation-across-healthcare-service-levels-for-medication-reviews-in-older-people-with 2024-09-13T10:50:24+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cooperation-across-healthcare-service-levels-for-medication-reviews-in-older-people-with 2024-09-13T10:50:24+00:00 weekly 0.7 https://trial.medpath.com/news/nvo-with-obesity-drug-demand-surging-is-novo-nordisk-a-buy-stocknews 2024-09-13T10:47:52+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nvo-with-obesity-drug-demand-surging-is-novo-nordisk-a-buy-stocknews 2024-09-13T10:47:52+00:00 weekly 0.7 https://trial.medpath.com/news/better-quicker-and-more-effective-treatment-for-patients-with-sepsis 2024-09-13T10:14:54+00:00 weekly 0.7 https://trial.medpath.com/zh/news/better-quicker-and-more-effective-treatment-for-patients-with-sepsis 2024-09-13T10:14:54+00:00 weekly 0.7 https://trial.medpath.com/news/ozempic-mounjaro-help-people-with-type-1-diabetes-control-blood-sugar-lose-weight 2024-09-13T10:09:25+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ozempic-mounjaro-help-people-with-type-1-diabetes-control-blood-sugar-lose-weight 2024-09-13T10:09:25+00:00 weekly 0.7 https://trial.medpath.com/news/trial-of-67cu-sar-bispsma-in-mcrpc-progresses-through-multi-dose-cohort 2024-09-13T10:04:53+00:00 weekly 0.7 https://trial.medpath.com/zh/news/trial-of-67cu-sar-bispsma-in-mcrpc-progresses-through-multi-dose-cohort 2024-09-13T10:04:53+00:00 weekly 0.7 https://trial.medpath.com/news/who-prequalifies-the-first-vaccine-against-mpox 2024-09-13T09:05:42+00:00 weekly 0.7 https://trial.medpath.com/zh/news/who-prequalifies-the-first-vaccine-against-mpox 2024-09-13T09:05:42+00:00 weekly 0.7 https://trial.medpath.com/news/us-fda-approves-injectable-version-of-roche-s-multiple-sclerosis-therapy-wtvb-1590-am 2024-09-13T09:02:34+00:00 weekly 0.7 https://trial.medpath.com/zh/news/us-fda-approves-injectable-version-of-roche-s-multiple-sclerosis-therapy-wtvb-1590-am 2024-09-13T09:02:34+00:00 weekly 0.7 https://trial.medpath.com/news/pharmacovigilance-study-of-the-association-between-peripheral-neuropathy-and-antibody-nature 2024-09-13T08:57:14+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pharmacovigilance-study-of-the-association-between-peripheral-neuropathy-and-antibody-nature 2024-09-13T08:57:14+00:00 weekly 0.7 https://trial.medpath.com/news/nordic-clinical-trials-conference-to-address-key-industry-challenges-and-innovation-in-copenhagen 2024-09-13T08:50:44+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nordic-clinical-trials-conference-to-address-key-industry-challenges-and-innovation-in-copenhagen 2024-09-13T08:50:44+00:00 weekly 0.7 https://trial.medpath.com/news/sjpedpanel-a-pan-cancer-gene-panel-for-childhood-malignancies-to-enhance-aacr-journals 2024-09-13T08:20:48+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sjpedpanel-a-pan-cancer-gene-panel-for-childhood-malignancies-to-enhance-aacr-journals 2024-09-13T08:20:48+00:00 weekly 0.7 https://trial.medpath.com/news/nanoscope-therapeutics-announces-end-of-phase-2-meeting-with-u-s-fda-and-plan-to 2024-09-13T08:04:59+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nanoscope-therapeutics-announces-end-of-phase-2-meeting-with-u-s-fda-and-plan-to 2024-09-13T08:04:59+00:00 weekly 0.7 https://trial.medpath.com/news/nxera-s-partner-cancer-research-uk-to-present-on-phase-1-2a-clinical-trial-with-biospace 2024-09-13T07:54:41+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nxera-s-partner-cancer-research-uk-to-present-on-phase-1-2a-clinical-trial-with-biospace 2024-09-13T07:54:41+00:00 weekly 0.7 https://trial.medpath.com/news/stapokibart-was-granted-marketing-approval-from-national-medical-products-biospace 2024-09-13T07:42:25+00:00 weekly 0.7 https://trial.medpath.com/zh/news/stapokibart-was-granted-marketing-approval-from-national-medical-products-biospace 2024-09-13T07:42:25+00:00 weekly 0.7 https://trial.medpath.com/news/nkgen-biotech-s-positive-phase-1-clinical-data-in-moderate-alzheimer-s-disease-advances 2024-09-13T07:42:15+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nkgen-biotech-s-positive-phase-1-clinical-data-in-moderate-alzheimer-s-disease-advances 2024-09-13T07:42:15+00:00 weekly 0.7 https://trial.medpath.com/news/moberg-pharma-ab-receives-information-about-clinical-cure-in-a-subset-of-patients-in-the 2024-09-13T07:06:23+00:00 weekly 0.7 https://trial.medpath.com/zh/news/moberg-pharma-ab-receives-information-about-clinical-cure-in-a-subset-of-patients-in-the 2024-09-13T07:06:23+00:00 weekly 0.7 https://trial.medpath.com/news/world-sepsis-day-highlights-critical-need-for-better-trial-design-and-targeted-therapeutics 2024-09-13T06:59:58+00:00 weekly 0.7 https://trial.medpath.com/zh/news/world-sepsis-day-highlights-critical-need-for-better-trial-design-and-targeted-therapeutics 2024-09-13T06:59:58+00:00 weekly 0.7 https://trial.medpath.com/news/international-research-team-proposes-multimodal-treatment-strategy-for-long-covid-and-post-acute-infectious-syndromes 2024-09-13T06:19:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/international-research-team-proposes-multimodal-treatment-strategy-for-long-covid-and-post-acute-infectious-syndromes 2024-09-13T06:19:00+00:00 weekly 0.7 https://trial.medpath.com/news/two-more-new-drugs-approved-under-1-mechanism 2024-09-13T05:25:16+00:00 weekly 0.7 https://trial.medpath.com/zh/news/two-more-new-drugs-approved-under-1-mechanism 2024-09-13T05:25:16+00:00 weekly 0.7 https://trial.medpath.com/news/increased-antimicrobial-use-precedes-b-cell-cancer-diagnosis-by-up-to-a-decade-danish-study-reveals 2024-09-13T05:14:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/increased-antimicrobial-use-precedes-b-cell-cancer-diagnosis-by-up-to-a-decade-danish-study-reveals 2024-09-13T05:14:00+00:00 weekly 0.7 https://trial.medpath.com/news/research-seeks-to-leverage-ai-behavioral-data-to-improve-mental-health 2024-09-13T04:53:21+00:00 weekly 0.7 https://trial.medpath.com/zh/news/research-seeks-to-leverage-ai-behavioral-data-to-improve-mental-health 2024-09-13T04:53:21+00:00 weekly 0.7 https://trial.medpath.com/news/less-toxic-more-personalized-treatments-on-the-horizon-in-her2-breast-cancer 2024-09-13T04:14:49+00:00 weekly 0.7 https://trial.medpath.com/zh/news/less-toxic-more-personalized-treatments-on-the-horizon-in-her2-breast-cancer 2024-09-13T04:14:49+00:00 weekly 0.7 https://trial.medpath.com/news/investigator-initiated-clinical-studies-to-be-launched-following-confirmation-of-tumor 2024-09-13T03:42:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/investigator-initiated-clinical-studies-to-be-launched-following-confirmation-of-tumor 2024-09-13T03:42:13+00:00 weekly 0.7 https://trial.medpath.com/news/fda-denies-accelerated-approval-path-for-moderna-merck-s-ai-driven-melanoma-vaccine 2024-09-13T03:11:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-denies-accelerated-approval-path-for-moderna-merck-s-ai-driven-melanoma-vaccine 2024-09-13T03:11:30+00:00 weekly 0.7 https://trial.medpath.com/news/moderna-scales-back-rsv-ambitions-cuts-pipeline-programs-amid-market-challenges 2024-09-13T03:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/moderna-scales-back-rsv-ambitions-cuts-pipeline-programs-amid-market-challenges 2024-09-13T03:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/halozyme-announces-fda-approval-of-roche-s-tecentriq-hybrezatm-with-enhanze-r-for 2024-09-13T01:52:11+00:00 weekly 0.7 https://trial.medpath.com/zh/news/halozyme-announces-fda-approval-of-roche-s-tecentriq-hybrezatm-with-enhanze-r-for 2024-09-13T01:52:11+00:00 weekly 0.7 https://trial.medpath.com/news/equitable-breakthroughs-in-medicine-development-eqbmed-to-work-with-inaugural 2024-09-13T01:00:51+00:00 weekly 0.7 https://trial.medpath.com/zh/news/equitable-breakthroughs-in-medicine-development-eqbmed-to-work-with-inaugural 2024-09-13T01:00:51+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-lilly-s-ebglyss-lebrikizumab-for-atopic-dermatitis 2024-09-13T00:09:18+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-lilly-s-ebglyss-lebrikizumab-for-atopic-dermatitis 2024-09-13T00:09:18+00:00 weekly 0.7 https://trial.medpath.com/news/telitacicept-shows-promise-as-alternative-treatment-for-iga-nephropathy-in-real-world-study 2024-09-13T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/telitacicept-shows-promise-as-alternative-treatment-for-iga-nephropathy-in-real-world-study 2024-09-13T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/ai-technology-revolutionizes-pharmaceutical-supply-chain-management-to-combat-drug-shortages 2024-09-13T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ai-technology-revolutionizes-pharmaceutical-supply-chain-management-to-combat-drug-shortages 2024-09-13T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-subcutaneous-atezolizumab-and-hyaluronidase-tqjs-for-use-in-all-onclive 2024-09-12T22:34:38+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-subcutaneous-atezolizumab-and-hyaluronidase-tqjs-for-use-in-all-onclive 2024-09-12T22:34:38+00:00 weekly 0.7 https://trial.medpath.com/news/gilead-s-twice-yearly-lenacapavir-for-hiv-prevention-reduced-hiv-infections-by-96-and 2024-09-12T22:16:58+00:00 weekly 0.7 https://trial.medpath.com/zh/news/gilead-s-twice-yearly-lenacapavir-for-hiv-prevention-reduced-hiv-infections-by-96-and 2024-09-12T22:16:58+00:00 weekly 0.7 https://trial.medpath.com/news/cvrx-touts-positive-two-year-data-for-heart-failure-neuromodulation-device 2024-09-12T22:15:16+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cvrx-touts-positive-two-year-data-for-heart-failure-neuromodulation-device 2024-09-12T22:15:16+00:00 weekly 0.7 https://trial.medpath.com/news/neurocrine-biosciences-provides-update-on-eruditetm-phase-2-data-for-luvadaxistat-in 2024-09-12T21:08:32+00:00 weekly 0.7 https://trial.medpath.com/zh/news/neurocrine-biosciences-provides-update-on-eruditetm-phase-2-data-for-luvadaxistat-in 2024-09-12T21:08:32+00:00 weekly 0.7 https://trial.medpath.com/news/alio-launches-calibration-and-validation-cava-study-to-expand-alio-platform-s-fda-biospace 2024-09-12T21:08:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/alio-launches-calibration-and-validation-cava-study-to-expand-alio-platform-s-fda-biospace 2024-09-12T21:08:30+00:00 weekly 0.7 https://trial.medpath.com/news/immuneering-announces-positive-initial-phase-2a-data 2024-09-12T21:06:34+00:00 weekly 0.7 https://trial.medpath.com/zh/news/immuneering-announces-positive-initial-phase-2a-data 2024-09-12T21:06:34+00:00 weekly 0.7 https://trial.medpath.com/news/bridgebio-grows-up-trims-pipeline-as-it-leans-into-late-stage-assets-biospace 2024-09-12T20:44:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bridgebio-grows-up-trims-pipeline-as-it-leans-into-late-stage-assets-biospace 2024-09-12T20:44:26+00:00 weekly 0.7 https://trial.medpath.com/news/heartsciences-provides-business-update-and-reports-first-quarter-fiscal-2025-financial-results 2024-09-12T20:20:31+00:00 weekly 0.7 https://trial.medpath.com/zh/news/heartsciences-provides-business-update-and-reports-first-quarter-fiscal-2025-financial-results 2024-09-12T20:20:31+00:00 weekly 0.7 https://trial.medpath.com/news/zambon-announces-publication-of-phase-3-promis-i-and-ii-study-results-in-the-lancet 2024-09-12T20:13:06+00:00 weekly 0.7 https://trial.medpath.com/zh/news/zambon-announces-publication-of-phase-3-promis-i-and-ii-study-results-in-the-lancet 2024-09-12T20:13:06+00:00 weekly 0.7 https://trial.medpath.com/news/association-of-statin-metformin-and-aspirin-use-with-hepatocellular-carcinoma-in-the-all-of 2024-09-12T18:08:42+00:00 weekly 0.7 https://trial.medpath.com/zh/news/association-of-statin-metformin-and-aspirin-use-with-hepatocellular-carcinoma-in-the-all-of 2024-09-12T18:08:42+00:00 weekly 0.7 https://trial.medpath.com/news/cancer-stage-vs-mortality-end-points-in-randomized-clinical-trials-of-cancer-screening 2024-09-12T17:58:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cancer-stage-vs-mortality-end-points-in-randomized-clinical-trials-of-cancer-screening 2024-09-12T17:58:30+00:00 weekly 0.7 https://trial.medpath.com/news/spark-biomedical-awarded-national-institute-on-drug-abuse-funding-to-develop-ai-morningstar 2024-09-12T17:55:08+00:00 weekly 0.7 https://trial.medpath.com/zh/news/spark-biomedical-awarded-national-institute-on-drug-abuse-funding-to-develop-ai-morningstar 2024-09-12T17:55:08+00:00 weekly 0.7 https://trial.medpath.com/news/digital-twin-technology-may-serve-as-soc-control-in-gvhd-trial-targeted-oncology 2024-09-12T17:46:55+00:00 weekly 0.7 https://trial.medpath.com/zh/news/digital-twin-technology-may-serve-as-soc-control-in-gvhd-trial-targeted-oncology 2024-09-12T17:46:55+00:00 weekly 0.7 https://trial.medpath.com/news/omrx-oncology-launches-to-advance-investigational-oral-checkpoint-inhibitor-designed-to 2024-09-12T17:46:25+00:00 weekly 0.7 https://trial.medpath.com/zh/news/omrx-oncology-launches-to-advance-investigational-oral-checkpoint-inhibitor-designed-to 2024-09-12T17:46:25+00:00 weekly 0.7 https://trial.medpath.com/news/sansum-diabetes-research-institute-is-actively-recruiting-patients-for-pediatric-clinical-trials 2024-09-12T17:25:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sansum-diabetes-research-institute-is-actively-recruiting-patients-for-pediatric-clinical-trials 2024-09-12T17:25:13+00:00 weekly 0.7 https://trial.medpath.com/news/oxford-heartbeat-completes-patient-recruitment-in-trial-evaluating-presize-neurovascular-software 2024-09-12T17:19:54+00:00 weekly 0.7 https://trial.medpath.com/zh/news/oxford-heartbeat-completes-patient-recruitment-in-trial-evaluating-presize-neurovascular-software 2024-09-12T17:19:54+00:00 weekly 0.7 https://trial.medpath.com/news/use-of-21-valent-pneumococcal-conjugate-vaccine-among-u-s-adults-cdc 2024-09-12T17:03:44+00:00 weekly 0.7 https://trial.medpath.com/zh/news/use-of-21-valent-pneumococcal-conjugate-vaccine-among-u-s-adults-cdc 2024-09-12T17:03:44+00:00 weekly 0.7 https://trial.medpath.com/news/tumor-induced-b-cell-changes-reveal-potential-biomarker-for-treatment-response-in-triple 2024-09-12T16:25:31+00:00 weekly 0.7 https://trial.medpath.com/zh/news/tumor-induced-b-cell-changes-reveal-potential-biomarker-for-treatment-response-in-triple 2024-09-12T16:25:31+00:00 weekly 0.7 https://trial.medpath.com/news/fda-gives-authorization-for-first-over-the-counter-hearing-aid-software-device-hcplive 2024-09-12T16:23:23+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-gives-authorization-for-first-over-the-counter-hearing-aid-software-device-hcplive 2024-09-12T16:23:23+00:00 weekly 0.7 https://trial.medpath.com/news/yunu-extends-free-cancer-center-use-of-platform-for-all-children-s-oncology-group-clinical-trials 2024-09-12T15:57:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/yunu-extends-free-cancer-center-use-of-platform-for-all-children-s-oncology-group-clinical-trials 2024-09-12T15:57:01+00:00 weekly 0.7 https://trial.medpath.com/news/curevac-partner-gsk-announces-positive-phase-2-data-from-seasonal-influenza-mrna 2024-09-12T15:45:46+00:00 weekly 0.7 https://trial.medpath.com/zh/news/curevac-partner-gsk-announces-positive-phase-2-data-from-seasonal-influenza-mrna 2024-09-12T15:45:46+00:00 weekly 0.7 https://trial.medpath.com/news/medtronic-scores-fda-approvals-for-several-new-therapies-to-drive-sales-star-tribune 2024-09-12T15:37:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/medtronic-scores-fda-approvals-for-several-new-therapies-to-drive-sales-star-tribune 2024-09-12T15:37:04+00:00 weekly 0.7 https://trial.medpath.com/news/shorter-course-radiation-better-option-for-breast-cancer-patients-than-conventional-schedule 2024-09-12T15:25:40+00:00 weekly 0.7 https://trial.medpath.com/zh/news/shorter-course-radiation-better-option-for-breast-cancer-patients-than-conventional-schedule 2024-09-12T15:25:40+00:00 weekly 0.7 https://trial.medpath.com/news/vera-therapeutics-completes-enrollment-for-primary-endpoint-in-pivotal-phase-3-origin-3 2024-09-12T15:16:46+00:00 weekly 0.7 https://trial.medpath.com/zh/news/vera-therapeutics-completes-enrollment-for-primary-endpoint-in-pivotal-phase-3-origin-3 2024-09-12T15:16:46+00:00 weekly 0.7 https://trial.medpath.com/news/richmond-clinical-trials-seeks-volunteers-for-vaccine-studies 2024-09-12T15:05:24+00:00 weekly 0.7 https://trial.medpath.com/zh/news/richmond-clinical-trials-seeks-volunteers-for-vaccine-studies 2024-09-12T15:05:24+00:00 weekly 0.7 https://trial.medpath.com/news/three-biotech-firms-secure-700m-in-major-ipo-wave-signaling-market-momentum 2024-09-12T15:02:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/three-biotech-firms-secure-700m-in-major-ipo-wave-signaling-market-momentum 2024-09-12T15:02:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-arthroscopic-knee-cartilage-repair-orthopedics-this-week 2024-09-12T14:45:32+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-arthroscopic-knee-cartilage-repair-orthopedics-this-week 2024-09-12T14:45:32+00:00 weekly 0.7 https://trial.medpath.com/news/trimodal-therapy-promising-for-recurrent-high-grade-t1-bladder-cancer 2024-09-12T14:20:35+00:00 weekly 0.7 https://trial.medpath.com/zh/news/trimodal-therapy-promising-for-recurrent-high-grade-t1-bladder-cancer 2024-09-12T14:20:35+00:00 weekly 0.7 https://trial.medpath.com/news/an-injectable-hiv-prevention-drug-is-highly-effective-but-wildly-expensive 2024-09-12T14:16:21+00:00 weekly 0.7 https://trial.medpath.com/zh/news/an-injectable-hiv-prevention-drug-is-highly-effective-but-wildly-expensive 2024-09-12T14:16:21+00:00 weekly 0.7 https://trial.medpath.com/news/matinee-mepolizumab-significantly-reduces-copd-exacerbations-pulmonology-advisor 2024-09-12T13:55:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/matinee-mepolizumab-significantly-reduces-copd-exacerbations-pulmonology-advisor 2024-09-12T13:55:17+00:00 weekly 0.7 https://trial.medpath.com/news/easd-2024-hightide-therapeutics-presents-oral-reports-of-phase-2-studies-highlighting 2024-09-12T13:20:21+00:00 weekly 0.7 https://trial.medpath.com/zh/news/easd-2024-hightide-therapeutics-presents-oral-reports-of-phase-2-studies-highlighting 2024-09-12T13:20:21+00:00 weekly 0.7 https://trial.medpath.com/news/tcbp-announces-first-patient-completed-the-full-fose-regimen-in-achieve-clinical-trial 2024-09-12T13:00:32+00:00 weekly 0.7 https://trial.medpath.com/zh/news/tcbp-announces-first-patient-completed-the-full-fose-regimen-in-achieve-clinical-trial 2024-09-12T13:00:32+00:00 weekly 0.7 https://trial.medpath.com/news/high-adderall-dose-linked-to-alarming-risk-of-mental-health-episodes 2024-09-12T12:49:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/high-adderall-dose-linked-to-alarming-risk-of-mental-health-episodes 2024-09-12T12:49:30+00:00 weekly 0.7 https://trial.medpath.com/news/f2g-raises-100m-to-bring-antifungal-drug-back-to-fda-biopharma-dive 2024-09-12T12:44:03+00:00 weekly 0.7 https://trial.medpath.com/zh/news/f2g-raises-100m-to-bring-antifungal-drug-back-to-fda-biopharma-dive 2024-09-12T12:44:03+00:00 weekly 0.7 https://trial.medpath.com/news/icecure-announces-fda-advisory-panel-meeting-date-for-marketing-authorization-pr-newswire 2024-09-12T12:33:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/icecure-announces-fda-advisory-panel-meeting-date-for-marketing-authorization-pr-newswire 2024-09-12T12:33:17+00:00 weekly 0.7 https://trial.medpath.com/news/alzheimer-s-clinical-trials-face-critical-diversity-challenge-experts-call-for-inclusive-enrollment 2024-09-12T12:23:40+00:00 weekly 0.7 https://trial.medpath.com/zh/news/alzheimer-s-clinical-trials-face-critical-diversity-challenge-experts-call-for-inclusive-enrollment 2024-09-12T12:23:40+00:00 weekly 0.7 https://trial.medpath.com/news/sernova-announces-new-positive-data-from-phase-i-ii-trial-regarding-islet-survival-and-function 2024-09-12T12:17:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sernova-announces-new-positive-data-from-phase-i-ii-trial-regarding-islet-survival-and-function 2024-09-12T12:17:04+00:00 weekly 0.7 https://trial.medpath.com/news/sinopia-secures-phase-ii-sbir-grant-from-the-national-institute-of-dental-and-craniofacial 2024-09-12T12:17:02+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sinopia-secures-phase-ii-sbir-grant-from-the-national-institute-of-dental-and-craniofacial 2024-09-12T12:17:02+00:00 weekly 0.7 https://trial.medpath.com/news/gsk-announces-positive-headline-data-from-phase-ii-seasonal-influenza-mrna-vaccine-programme 2024-09-12T12:04:25+00:00 weekly 0.7 https://trial.medpath.com/zh/news/gsk-announces-positive-headline-data-from-phase-ii-seasonal-influenza-mrna-vaccine-programme 2024-09-12T12:04:25+00:00 weekly 0.7 https://trial.medpath.com/news/bright-minds-biosciences-initiates-the-breakthrough-study-a-phase-2-trial-of-bmb-101 2024-09-12T12:00:44+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bright-minds-biosciences-initiates-the-breakthrough-study-a-phase-2-trial-of-bmb-101 2024-09-12T12:00:44+00:00 weekly 0.7 https://trial.medpath.com/news/vironexis-biotherapeutics-launches-with-fda-clearance-of-ind-application-for-first-ever 2024-09-12T11:49:40+00:00 weekly 0.7 https://trial.medpath.com/zh/news/vironexis-biotherapeutics-launches-with-fda-clearance-of-ind-application-for-first-ever 2024-09-12T11:49:40+00:00 weekly 0.7 https://trial.medpath.com/news/summit-therapeutics-raises-235m-for-cancer-drug-trials-tipranks-com 2024-09-12T11:36:12+00:00 weekly 0.7 https://trial.medpath.com/zh/news/summit-therapeutics-raises-235m-for-cancer-drug-trials-tipranks-com 2024-09-12T11:36:12+00:00 weekly 0.7 https://trial.medpath.com/news/world-first-florey-research-aims-to-rapidly-and-accurately-screen-drugs-to-treat-mnd 2024-09-12T11:31:12+00:00 weekly 0.7 https://trial.medpath.com/zh/news/world-first-florey-research-aims-to-rapidly-and-accurately-screen-drugs-to-treat-mnd 2024-09-12T11:31:12+00:00 weekly 0.7 https://trial.medpath.com/news/fulcrum-therapeutics-announces-topline-results-from-phase-3-reach-clinical-trial-of 2024-09-12T11:23:42+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fulcrum-therapeutics-announces-topline-results-from-phase-3-reach-clinical-trial-of 2024-09-12T11:23:42+00:00 weekly 0.7 https://trial.medpath.com/news/comparable-disease-activity-drug-persistence-in-patients-with-jia-who-switch-to-biosimilars 2024-09-12T11:02:23+00:00 weekly 0.7 https://trial.medpath.com/zh/news/comparable-disease-activity-drug-persistence-in-patients-with-jia-who-switch-to-biosimilars 2024-09-12T11:02:23+00:00 weekly 0.7 https://trial.medpath.com/news/positive-phase-ii-bolsters-aura-bioscience-s-confidence-in-vdc-based-therapy-for-ocular 2024-09-12T10:47:34+00:00 weekly 0.7 https://trial.medpath.com/zh/news/positive-phase-ii-bolsters-aura-bioscience-s-confidence-in-vdc-based-therapy-for-ocular 2024-09-12T10:47:34+00:00 weekly 0.7 https://trial.medpath.com/news/moderna-slashes-research-spending-trims-pipeline-as-it-looks-to-regain-footing-morningstar 2024-09-12T10:12:44+00:00 weekly 0.7 https://trial.medpath.com/zh/news/moderna-slashes-research-spending-trims-pipeline-as-it-looks-to-regain-footing-morningstar 2024-09-12T10:12:44+00:00 weekly 0.7 https://trial.medpath.com/news/weight-loss-drug-zepbound-may-work-better-in-women-than-men-healthday 2024-09-12T10:01:52+00:00 weekly 0.7 https://trial.medpath.com/zh/news/weight-loss-drug-zepbound-may-work-better-in-women-than-men-healthday 2024-09-12T10:01:52+00:00 weekly 0.7 https://trial.medpath.com/news/key-paediatric-milestone-reached-in-dimerix-s-kidney-disease-drug-trial-stockhead 2024-09-12T09:48:48+00:00 weekly 0.7 https://trial.medpath.com/zh/news/key-paediatric-milestone-reached-in-dimerix-s-kidney-disease-drug-trial-stockhead 2024-09-12T09:48:48+00:00 weekly 0.7 https://trial.medpath.com/news/doherty-clinical-trials-to-conduct-trial-of-australian-developed-needle-free-vaccine-for-avian 2024-09-12T09:48:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/doherty-clinical-trials-to-conduct-trial-of-australian-developed-needle-free-vaccine-for-avian 2024-09-12T09:48:13+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-breakthrough-therapy-designation-to-neuraptive-s-ntx-001 2024-09-12T09:36:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-grants-breakthrough-therapy-designation-to-neuraptive-s-ntx-001 2024-09-12T09:36:13+00:00 weekly 0.7 https://trial.medpath.com/news/alzheimer-s-drugs-may-work-in-whole-new-way-study-finds 2024-09-12T09:09:03+00:00 weekly 0.7 https://trial.medpath.com/zh/news/alzheimer-s-drugs-may-work-in-whole-new-way-study-finds 2024-09-12T09:09:03+00:00 weekly 0.7 https://trial.medpath.com/news/crispr-fixes-multiple-dystrophin-duplications-in-dmd-patient-cells 2024-09-12T09:03:22+00:00 weekly 0.7 https://trial.medpath.com/zh/news/crispr-fixes-multiple-dystrophin-duplications-in-dmd-patient-cells 2024-09-12T09:03:22+00:00 weekly 0.7 https://trial.medpath.com/news/pbm-transparency-crisis-industry-expert-calls-for-reform-to-improve-drug-access-and-pricing 2024-09-12T08:21:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pbm-transparency-crisis-industry-expert-calls-for-reform-to-improve-drug-access-and-pricing 2024-09-12T08:21:00+00:00 weekly 0.7 https://trial.medpath.com/news/cd137-antibodies-clinical-trials-market-opportunity-yahoo-finance 2024-09-12T08:16:11+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cd137-antibodies-clinical-trials-market-opportunity-yahoo-finance 2024-09-12T08:16:11+00:00 weekly 0.7 https://trial.medpath.com/news/september-12-2024-nih-collaboratory-biostatisticians-evaluate-analytic-models-for 2024-09-12T08:05:48+00:00 weekly 0.7 https://trial.medpath.com/zh/news/september-12-2024-nih-collaboratory-biostatisticians-evaluate-analytic-models-for 2024-09-12T08:05:48+00:00 weekly 0.7 https://trial.medpath.com/news/ryvu-therapeutics-reports-2024-half-year-financial-results-and-provides-corporate-update 2024-09-12T08:03:40+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ryvu-therapeutics-reports-2024-half-year-financial-results-and-provides-corporate-update 2024-09-12T08:03:40+00:00 weekly 0.7 https://trial.medpath.com/news/novotech-publishes-report-on-research-into-endometrial-cancer-a-leading-cause-of-massbio 2024-09-12T06:38:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/novotech-publishes-report-on-research-into-endometrial-cancer-a-leading-cause-of-massbio 2024-09-12T06:38:00+00:00 weekly 0.7 https://trial.medpath.com/news/novotech-report-analyses-epilepsy-research-trends-finding-more-than-4000-clinical-massbio 2024-09-12T06:37:59+00:00 weekly 0.7 https://trial.medpath.com/zh/news/novotech-report-analyses-epilepsy-research-trends-finding-more-than-4000-clinical-massbio 2024-09-12T06:37:59+00:00 weekly 0.7 https://trial.medpath.com/news/novotech-liver-cancer-research-landscape-report-finds-1700-trials-initiated-globally 2024-09-12T06:37:58+00:00 weekly 0.7 https://trial.medpath.com/zh/news/novotech-liver-cancer-research-landscape-report-finds-1700-trials-initiated-globally 2024-09-12T06:37:58+00:00 weekly 0.7 https://trial.medpath.com/news/new-report-highlights-global-trends-and-advances-in-chronic-lymphocytic-leukemia-massbio 2024-09-12T06:37:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-report-highlights-global-trends-and-advances-in-chronic-lymphocytic-leukemia-massbio 2024-09-12T06:37:56+00:00 weekly 0.7 https://trial.medpath.com/news/bmi-s-relation-to-cancer-therapy-mortality-risks-not-so-straightforward-eurekalert 2024-09-12T05:32:32+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bmi-s-relation-to-cancer-therapy-mortality-risks-not-so-straightforward-eurekalert 2024-09-12T05:32:32+00:00 weekly 0.7 https://trial.medpath.com/news/innate-pharma-reports-first-half-2024-business-update-and-financial-results-morningstar 2024-09-12T05:14:16+00:00 weekly 0.7 https://trial.medpath.com/zh/news/innate-pharma-reports-first-half-2024-business-update-and-financial-results-morningstar 2024-09-12T05:14:16+00:00 weekly 0.7 https://trial.medpath.com/news/press-release-sanofi-radiomedix-and-orano-med-announce-licensing-agreement-on-next 2024-09-12T05:12:28+00:00 weekly 0.7 https://trial.medpath.com/zh/news/press-release-sanofi-radiomedix-and-orano-med-announce-licensing-agreement-on-next 2024-09-12T05:12:28+00:00 weekly 0.7 https://trial.medpath.com/news/new-treatment-option-for-graves-disease-finally-on-the-horizon 2024-09-12T05:00:07+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-treatment-option-for-graves-disease-finally-on-the-horizon 2024-09-12T05:00:07+00:00 weekly 0.7 https://trial.medpath.com/news/in-depth-report-on-global-oesophageal-cancer-clinical-trials-now-available-massbio 2024-09-12T04:47:43+00:00 weekly 0.7 https://trial.medpath.com/zh/news/in-depth-report-on-global-oesophageal-cancer-clinical-trials-now-available-massbio 2024-09-12T04:47:43+00:00 weekly 0.7 https://trial.medpath.com/news/alx-oncology-s-evorpacept-gains-momentum-with-fda-fast-track-designations 2024-09-12T02:38:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/alx-oncology-s-evorpacept-gains-momentum-with-fda-fast-track-designations 2024-09-12T02:38:26+00:00 weekly 0.7 https://trial.medpath.com/news/clinical-development-of-gamma-delta-t-cell-therapy-inb-400-paused-in-glioblastoma 2024-09-12T02:10:12+00:00 weekly 0.7 https://trial.medpath.com/zh/news/clinical-development-of-gamma-delta-t-cell-therapy-inb-400-paused-in-glioblastoma 2024-09-12T02:10:12+00:00 weekly 0.7 https://trial.medpath.com/news/multimodal-analgesia-approach-in-acute-low-back-pain-management-a-phase-iii-study-of 2024-09-12T02:06:48+00:00 weekly 0.7 https://trial.medpath.com/zh/news/multimodal-analgesia-approach-in-acute-low-back-pain-management-a-phase-iii-study-of 2024-09-12T02:06:48+00:00 weekly 0.7 https://trial.medpath.com/news/two-stage-screening-for-obstructive-sleep-apnea-in-the-primary-practice-setting 2024-09-12T02:05:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/two-stage-screening-for-obstructive-sleep-apnea-in-the-primary-practice-setting 2024-09-12T02:05:09+00:00 weekly 0.7 https://trial.medpath.com/news/matregenix-awarded-three-phase-ii-sbir-and-sttr-contracts-from-the-department-of-the-air-force 2024-09-12T00:55:18+00:00 weekly 0.7 https://trial.medpath.com/zh/news/matregenix-awarded-three-phase-ii-sbir-and-sttr-contracts-from-the-department-of-the-air-force 2024-09-12T00:55:18+00:00 weekly 0.7 https://trial.medpath.com/news/kintara-therapeutics-provides-update-on-corporate-developments-and-rem-001-clinical-study 2024-09-12T00:31:16+00:00 weekly 0.7 https://trial.medpath.com/zh/news/kintara-therapeutics-provides-update-on-corporate-developments-and-rem-001-clinical-study 2024-09-12T00:31:16+00:00 weekly 0.7 https://trial.medpath.com/news/global-research-community-applies-covid-19-lessons-to-combat-african-mpox-emergency 2024-09-12T00:29:21+00:00 weekly 0.7 https://trial.medpath.com/zh/news/global-research-community-applies-covid-19-lessons-to-combat-african-mpox-emergency 2024-09-12T00:29:21+00:00 weekly 0.7 https://trial.medpath.com/news/is-the-hype-about-a-new-non-opioid-analgesic-justified-pain-news-network 2024-09-12T00:15:38+00:00 weekly 0.7 https://trial.medpath.com/zh/news/is-the-hype-about-a-new-non-opioid-analgesic-justified-pain-news-network 2024-09-12T00:15:38+00:00 weekly 0.7 https://trial.medpath.com/news/hydroxychloroquine-provides-moderate-covid-19-prevention-large 2024-09-12T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/hydroxychloroquine-provides-moderate-covid-19-prevention-large 2024-09-12T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/clinical-effectiveness-safety-and-compliance-of-two 2024-09-12T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/clinical-effectiveness-safety-and-compliance-of-two 2024-09-12T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/easd-2024-survodutide-shows-promise-in-overweight-obesity-and-mash 2024-09-11T23:54:12+00:00 weekly 0.7 https://trial.medpath.com/zh/news/easd-2024-survodutide-shows-promise-in-overweight-obesity-and-mash 2024-09-11T23:54:12+00:00 weekly 0.7 https://trial.medpath.com/news/a-phase-ii-study-of-neoadjuvant-nivolumab-and-nab-paclitaxel-followed-by-urotoday 2024-09-11T23:46:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/a-phase-ii-study-of-neoadjuvant-nivolumab-and-nab-paclitaxel-followed-by-urotoday 2024-09-11T23:46:09+00:00 weekly 0.7 https://trial.medpath.com/news/the-foundation-for-the-national-institutes-of-health-announces-study-results-published-in-fnih 2024-09-11T22:35:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/the-foundation-for-the-national-institutes-of-health-announces-study-results-published-in-fnih 2024-09-11T22:35:39+00:00 weekly 0.7 https://trial.medpath.com/news/phase-3-trial-shows-superior-survival-with-rilertinib-for-egfr-mutated-nsclc 2024-09-11T22:29:44+00:00 weekly 0.7 https://trial.medpath.com/zh/news/phase-3-trial-shows-superior-survival-with-rilertinib-for-egfr-mutated-nsclc 2024-09-11T22:29:44+00:00 weekly 0.7 https://trial.medpath.com/news/tremfya-r-guselkumab-receives-u-s-fda-approval-for-adults-with-moderately-to-pr-newswire 2024-09-11T22:23:07+00:00 weekly 0.7 https://trial.medpath.com/zh/news/tremfya-r-guselkumab-receives-u-s-fda-approval-for-adults-with-moderately-to-pr-newswire 2024-09-11T22:23:07+00:00 weekly 0.7 https://trial.medpath.com/news/ascendis-pharma-receives-orphan-drug-exclusivity-in-the-u-s-for-yorvipath-morningstar 2024-09-11T22:22:02+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ascendis-pharma-receives-orphan-drug-exclusivity-in-the-u-s-for-yorvipath-morningstar 2024-09-11T22:22:02+00:00 weekly 0.7 https://trial.medpath.com/news/conventional-complementary-and-integrative-pain-therapies-in-a-military-population-with 2024-09-11T21:46:42+00:00 weekly 0.7 https://trial.medpath.com/zh/news/conventional-complementary-and-integrative-pain-therapies-in-a-military-population-with 2024-09-11T21:46:42+00:00 weekly 0.7 https://trial.medpath.com/news/fda-clears-brain-mapping-tool-for-neuromodulation-therapies-parkinson-s-news-today 2024-09-11T21:16:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-clears-brain-mapping-tool-for-neuromodulation-therapies-parkinson-s-news-today 2024-09-11T21:16:13+00:00 weekly 0.7 https://trial.medpath.com/news/triluminate-update-teer-with-abbott-s-triclip-device-still-safe-effective-after-3-years 2024-09-11T21:13:59+00:00 weekly 0.7 https://trial.medpath.com/zh/news/triluminate-update-teer-with-abbott-s-triclip-device-still-safe-effective-after-3-years 2024-09-11T21:13:59+00:00 weekly 0.7 https://trial.medpath.com/news/norton-cancer-institute-patient-receives-first-in-world-clinical-trial-medicine-dos-louisville 2024-09-11T20:25:55+00:00 weekly 0.7 https://trial.medpath.com/zh/news/norton-cancer-institute-patient-receives-first-in-world-clinical-trial-medicine-dos-louisville 2024-09-11T20:25:55+00:00 weekly 0.7 https://trial.medpath.com/news/studies-show-safety-efficacy-of-rsv-preventive-drug-in-kids-cidrap 2024-09-11T20:25:54+00:00 weekly 0.7 https://trial.medpath.com/zh/news/studies-show-safety-efficacy-of-rsv-preventive-drug-in-kids-cidrap 2024-09-11T20:25:54+00:00 weekly 0.7 https://trial.medpath.com/news/biopharma-company-sues-dea-for-unjustified-delays-in-approving-cannabis-research 2024-09-11T20:05:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/biopharma-company-sues-dea-for-unjustified-delays-in-approving-cannabis-research 2024-09-11T20:05:13+00:00 weekly 0.7 https://trial.medpath.com/news/dr-danilov-on-ongoing-mcl-clinical-trials-onclive 2024-09-11T19:57:41+00:00 weekly 0.7 https://trial.medpath.com/zh/news/dr-danilov-on-ongoing-mcl-clinical-trials-onclive 2024-09-11T19:57:41+00:00 weekly 0.7 https://trial.medpath.com/news/expanding-possibilities-dana-farber-cancer-institute 2024-09-11T19:54:11+00:00 weekly 0.7 https://trial.medpath.com/zh/news/expanding-possibilities-dana-farber-cancer-institute 2024-09-11T19:54:11+00:00 weekly 0.7 https://trial.medpath.com/news/fda-reviewers-skeptical-of-ocaliva-for-rare-bile-duct-disease-medpage-today 2024-09-11T19:44:25+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-reviewers-skeptical-of-ocaliva-for-rare-bile-duct-disease-medpage-today 2024-09-11T19:44:25+00:00 weekly 0.7 https://trial.medpath.com/news/dedicated-trialist-nurse-navigators-help-advance-cancer-therapy-into-accelerated-approval 2024-09-11T19:25:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/dedicated-trialist-nurse-navigators-help-advance-cancer-therapy-into-accelerated-approval 2024-09-11T19:25:26+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-510-k-clearance-to-under-mattress-device-that-assists-in-osa-diagnosis-healio 2024-09-11T19:16:34+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-grants-510-k-clearance-to-under-mattress-device-that-assists-in-osa-diagnosis-healio 2024-09-11T19:16:34+00:00 weekly 0.7 https://trial.medpath.com/news/eortc-extends-medidata-partnership-to-help-power-new-phase-of-oncology-research 2024-09-11T18:54:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/eortc-extends-medidata-partnership-to-help-power-new-phase-of-oncology-research 2024-09-11T18:54:13+00:00 weekly 0.7 https://trial.medpath.com/news/bria-imt-plus-checkpoint-inhibition-maintains-favorable-os-in-metastatic-breast-cancer 2024-09-11T18:44:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bria-imt-plus-checkpoint-inhibition-maintains-favorable-os-in-metastatic-breast-cancer 2024-09-11T18:44:56+00:00 weekly 0.7 https://trial.medpath.com/news/obesity-key-pipeline-developments-and-clinical-trial-insights-iqvia 2024-09-11T18:39:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/obesity-key-pipeline-developments-and-clinical-trial-insights-iqvia 2024-09-11T18:39:13+00:00 weekly 0.7 https://trial.medpath.com/news/mounjaro-expanded-to-include-weight-management-racgp 2024-09-11T18:02:45+00:00 weekly 0.7 https://trial.medpath.com/zh/news/mounjaro-expanded-to-include-weight-management-racgp 2024-09-11T18:02:45+00:00 weekly 0.7 https://trial.medpath.com/news/basking-biosciences-doses-first-subject-in-phase-ii-acute-ischaemic-stroke-trial 2024-09-11T17:49:57+00:00 weekly 0.7 https://trial.medpath.com/zh/news/basking-biosciences-doses-first-subject-in-phase-ii-acute-ischaemic-stroke-trial 2024-09-11T17:49:57+00:00 weekly 0.7 https://trial.medpath.com/news/incendia-enrols-first-subject-in-phase-ic-advanced-solid-tumour-trial 2024-09-11T17:47:50+00:00 weekly 0.7 https://trial.medpath.com/zh/news/incendia-enrols-first-subject-in-phase-ic-advanced-solid-tumour-trial 2024-09-11T17:47:50+00:00 weekly 0.7 https://trial.medpath.com/news/china-boosts-regulatory-framework-for-local-pharmaceutical-manufacturing 2024-09-11T17:44:44+00:00 weekly 0.7 https://trial.medpath.com/zh/news/china-boosts-regulatory-framework-for-local-pharmaceutical-manufacturing 2024-09-11T17:44:44+00:00 weekly 0.7 https://trial.medpath.com/news/akebia-readies-launch-of-anemia-drug-vafseo-planning-talks-with-fda-on-pre-dialysis-use 2024-09-11T17:02:47+00:00 weekly 0.7 https://trial.medpath.com/zh/news/akebia-readies-launch-of-anemia-drug-vafseo-planning-talks-with-fda-on-pre-dialysis-use 2024-09-11T17:02:47+00:00 weekly 0.7 https://trial.medpath.com/news/a-new-fentanyl-vaccine-looks-promising-but-treating-drug-addiction-needs-a-more-complex 2024-09-11T16:24:25+00:00 weekly 0.7 https://trial.medpath.com/zh/news/a-new-fentanyl-vaccine-looks-promising-but-treating-drug-addiction-needs-a-more-complex 2024-09-11T16:24:25+00:00 weekly 0.7 https://trial.medpath.com/news/eu-clinical-trial-regulation-what-does-it-aim-to-achieve 2024-09-11T16:18:40+00:00 weekly 0.7 https://trial.medpath.com/zh/news/eu-clinical-trial-regulation-what-does-it-aim-to-achieve 2024-09-11T16:18:40+00:00 weekly 0.7 https://trial.medpath.com/news/culturally-adapted-lifestyle-intervention-for-south-asian-adults-with-cardiovascular-risk-factors 2024-09-11T16:17:43+00:00 weekly 0.7 https://trial.medpath.com/zh/news/culturally-adapted-lifestyle-intervention-for-south-asian-adults-with-cardiovascular-risk-factors 2024-09-11T16:17:43+00:00 weekly 0.7 https://trial.medpath.com/news/diabetes-drug-helps-the-immune-system-recognize-reservoirs-of-hiv-study-discovers 2024-09-11T16:12:54+00:00 weekly 0.7 https://trial.medpath.com/zh/news/diabetes-drug-helps-the-immune-system-recognize-reservoirs-of-hiv-study-discovers 2024-09-11T16:12:54+00:00 weekly 0.7 https://trial.medpath.com/news/veligrotug-for-treatment-of-thyroid-eye-disease-meets-endpoints-in-phase-3-trial-healio 2024-09-11T16:04:47+00:00 weekly 0.7 https://trial.medpath.com/zh/news/veligrotug-for-treatment-of-thyroid-eye-disease-meets-endpoints-in-phase-3-trial-healio 2024-09-11T16:04:47+00:00 weekly 0.7 https://trial.medpath.com/news/actuate-receives-fda-orphan-drug-designation-for-elraglusib-for-treatment-of-soft-tissue 2024-09-11T15:51:03+00:00 weekly 0.7 https://trial.medpath.com/zh/news/actuate-receives-fda-orphan-drug-designation-for-elraglusib-for-treatment-of-soft-tissue 2024-09-11T15:51:03+00:00 weekly 0.7 https://trial.medpath.com/news/vla1553-chikungunya-virus-vaccine-shows-antibody-persistence-up-to-2-years-following 2024-09-11T15:47:14+00:00 weekly 0.7 https://trial.medpath.com/zh/news/vla1553-chikungunya-virus-vaccine-shows-antibody-persistence-up-to-2-years-following 2024-09-11T15:47:14+00:00 weekly 0.7 https://trial.medpath.com/news/vaxxas-initiates-phase-i-clinical-trial-of-pre-pandemic-avian-influenza-a-virus-h7n9-biospace 2024-09-11T15:10:18+00:00 weekly 0.7 https://trial.medpath.com/zh/news/vaxxas-initiates-phase-i-clinical-trial-of-pre-pandemic-avian-influenza-a-virus-h7n9-biospace 2024-09-11T15:10:18+00:00 weekly 0.7 https://trial.medpath.com/news/ultimovacs-announces-patient-recruitment-discontinuation-in-globenewswire 2024-09-11T15:09:34+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ultimovacs-announces-patient-recruitment-discontinuation-in-globenewswire 2024-09-11T15:09:34+00:00 weekly 0.7 https://trial.medpath.com/news/blood-cell-counts-have-unfairly-kept-black-and-middle-eastern-people-from-clinical-trials-study-says 2024-09-11T15:04:46+00:00 weekly 0.7 https://trial.medpath.com/zh/news/blood-cell-counts-have-unfairly-kept-black-and-middle-eastern-people-from-clinical-trials-study-says 2024-09-11T15:04:46+00:00 weekly 0.7 https://trial.medpath.com/news/vertex-crispr-s-casgevy-faces-complex-path-to-profitability-biospace 2024-09-11T15:03:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/vertex-crispr-s-casgevy-faces-complex-path-to-profitability-biospace 2024-09-11T15:03:39+00:00 weekly 0.7 https://trial.medpath.com/news/adapt-a-clinical-trial-of-adaptive-treatment-for-early-smoking-cessation-relapse-uab 2024-09-11T15:01:10+00:00 weekly 0.7 https://trial.medpath.com/zh/news/adapt-a-clinical-trial-of-adaptive-treatment-for-early-smoking-cessation-relapse-uab 2024-09-11T15:01:10+00:00 weekly 0.7 https://trial.medpath.com/news/johnson-johnson-reports-data-from-phase-ii-nsclc-treatment-trial-clinical-trials-arena 2024-09-11T14:58:48+00:00 weekly 0.7 https://trial.medpath.com/zh/news/johnson-johnson-reports-data-from-phase-ii-nsclc-treatment-trial-clinical-trials-arena 2024-09-11T14:58:48+00:00 weekly 0.7 https://trial.medpath.com/news/sotatercept-gains-european-approval-for-pah-for-use-with-other-treatments 2024-09-11T14:57:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sotatercept-gains-european-approval-for-pah-for-use-with-other-treatments 2024-09-11T14:57:01+00:00 weekly 0.7 https://trial.medpath.com/news/merck-announces-positive-top-line-results-from-phase-3-trial-evaluating-efficacy-and 2024-09-11T14:52:15+00:00 weekly 0.7 https://trial.medpath.com/zh/news/merck-announces-positive-top-line-results-from-phase-3-trial-evaluating-efficacy-and 2024-09-11T14:52:15+00:00 weekly 0.7 https://trial.medpath.com/news/entero-signs-letter-of-intent-to-license-and-commercialize-remote-patient-and-machine-vision 2024-09-11T14:30:36+00:00 weekly 0.7 https://trial.medpath.com/zh/news/entero-signs-letter-of-intent-to-license-and-commercialize-remote-patient-and-machine-vision 2024-09-11T14:30:36+00:00 weekly 0.7 https://trial.medpath.com/news/dcgi-suspends-entod-s-marketing-approval-for-presvu-eye-drops-amid-misuse-concerns 2024-09-11T14:24:02+00:00 weekly 0.7 https://trial.medpath.com/zh/news/dcgi-suspends-entod-s-marketing-approval-for-presvu-eye-drops-amid-misuse-concerns 2024-09-11T14:24:02+00:00 weekly 0.7 https://trial.medpath.com/news/indies-pharma-gets-fda-approval-on-new-drug-jamaica-observer 2024-09-11T14:13:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/indies-pharma-gets-fda-approval-on-new-drug-jamaica-observer 2024-09-11T14:13:26+00:00 weekly 0.7 https://trial.medpath.com/news/real-world-data-support-use-of-rpfviii-for-acquired-hemophilia-a-hcplive 2024-09-11T14:06:22+00:00 weekly 0.7 https://trial.medpath.com/zh/news/real-world-data-support-use-of-rpfviii-for-acquired-hemophilia-a-hcplive 2024-09-11T14:06:22+00:00 weekly 0.7 https://trial.medpath.com/news/sarepta-s-like-a-curse-on-me-fda-commissioner-califf-says-stat-news 2024-09-11T13:57:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sarepta-s-like-a-curse-on-me-fda-commissioner-califf-says-stat-news 2024-09-11T13:57:39+00:00 weekly 0.7 https://trial.medpath.com/news/mhra-authorization-of-dupixent-dupilumab-marks-a-significant-step-forward-as-the-uk 2024-09-11T13:53:47+00:00 weekly 0.7 https://trial.medpath.com/zh/news/mhra-authorization-of-dupixent-dupilumab-marks-a-significant-step-forward-as-the-uk 2024-09-11T13:53:47+00:00 weekly 0.7